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ABSTRACT
DENISE L. MATTHEWS.  Studies in Chemical Toxicology:Synthesis of a Protected N -Deoxyguanosine Adduct of aCyclopenta-Polycyclic Aromatic Hydrocarbon.  (Under the
Direction of Dr. AVRAM GOLD)
A pilot synthesis was undertaken to develop synthetic routes
for synthesis of N^-deoxyguanosine adducts of a cyclopenta-
polycyclic aromatic hydrocarbon (CP-PAH), which have
potential application for use as chromatographic standards
in the -^^P-postlabeling assay.  A straightforward synthetic
route was developed for the synthesis of an 0°-p-
nitrophenylethyl(NPE) and 3',5'-p-toluoyl group protected
derivative of 2-bromo-2'-deoxyinosine(2-BrdI) (compound 6B).
The successful strategy involved sodium salt gylcosylation
of 0^-NPE-protected 2-bromohypoxanthine (4) with 2-deoxy-
3.5-di-O-p-toluoyl- g-D-erythro pentofuranosyl chloride (5B)
to give desired pure N-9 6 glycosylation product (6B) in 39%
yield.  The direct glycosylation product (6B) was coupled
with a CP-PAH amino alcohol, trans acenaphthene l-amino-2-ol
(7), to generate the first example of a protected N^-
deoxyguanosine adduct of a CP-PAH (compound 8) in'*'5% yield.
This successful condensation reaction proved the usefulness
of the protected 2-BrdI derivative (6B) as a precursor to
target N^-modified-2'-deoxyguanosine.  The p-toluoyl groups
can be removed by ammonolysis of compound 6B to give 0°-NPE-
protected-2-BrdI in 63% yield.  The structural identity and
purity of reaction products were confirmed by -' ͣH NMR and
mass spectra.
ill
ACKNOWLEDGMENTS
I would like to deeply thank Dr. Avram Gold for his
personal interest, support, and guidance during my research
studies in the Department of Environmental Sciences and
Engineering.  I am also very grateful to fellow laboratory
workers and friends including Rick, Rachel, Kirstin, Dr.
Sangaiah, and Dr. Jayaraj for all of their never-ending
support and encouragement throughout my research project.  I
especially appreciate Dr. Sangaiah for his help and guidance
in synthetic organic chemistry.  He was a true inspiration
during this investigation.  I am also grateful to Dr. Ball
and Dr. Rappaport for their suggestions and support during
the preparation of this technical report.
The United States Coast Guard sponsored my education at
Environmental Sciences and Engineering.  This investigation
was conducted as a part of a research program supported in
part by USPHS grant #CA47965.
ͣ '«i;W*.JiJ^y
IV
TABLE OF CONTENTS
Page
ACKNOWLEDGMENTS .........................................iii
LIST OF TABLES...........................................vi
LIST OF FIGURES .........................................vii
Chapter
I.  INTRODUCTION........................................1
II.  LITERATURE REVIEW...................................6
General Mechanism of Chemical Carcinogenesis ......6Metabolism of Xenobiotics in Relation toDNA Adduct Formation ...........................10
Metabolic Activation of Alternant PAH.......13
Metabolic Activation of Cyclopenta-PAH......18Molecular Sites on DNA Susceptible toCovalent Reactions ........................25
Methods of Identification and Quantitation ofDNA Adducts ....................................26ͣ^^P-Postlabeling Techniques .................28
Application to DNA Adductsof Cyclopenta-PAH .....................31Use of DNA Adducts in Human Biomonitoring........34Detection of Aromatic DNA Adducts in HumanTissues by ^^P-Postlabeling...............38
III.  EXPERIMENTAL MATERIALS AND METHODS................. 41
Basis for Synthetic Approach .....................41Instrumentation and Laboratory Materials .........45
Synthesis of 0°-NPE-Protected2-Bromohypoxanthine (4) ........................472-Bromohypoxanthine (1) .....................47Tritylated 2-Bromohypoxanthine (2) ..........47Tritylated 2-Bromo-0°-p-nitrophenylethylpurine {3) ................................482-Bromo-0°-p-nitrophenylethylpurine (4) .....49Lewis Acid Catalyzed Glycosylation of 0°-NPE-Protected 2-Bromohypoxanthine (4) ..........521,3,5-Tri-0-acetyl-2-deoxy-a^ B-D-erythro-pentofuranose (5A) ........................522-Bromo-0°-p-nitrophenylethyl-9-(2-deoxy-3,5-di-O-acetyl-B-D-erythro-pentofuranosyl)purine (6A) and Its Isomers ...............52
Sodium Salt Glycosylation of 0 -NPE-Protected2-Bromohypoxanthine (4) ........................552-Deoxy-3,5-di-O-p-toluoyl-a-D-erythro-pentofuranosyl chloride (5B) ..............55
2-Bromo-0^-p-nitrophenylethyl-9-(2-deoxy-
3,5-di-O-p-toluoyl-fi-D-erythro-
pentofuranosyl)purine (6B)and Its 7-6 Isomer ........................55
Condensation of Glycosylation Product (6B) withCyclopenta-PAH amino alcohol (7) ...............61Trans acenaphthene l-amino-2-ol (7) .........61N^-[1-(trans-2-hydroxy-acenaphthenyl)]-0°-p-nitrophenylethyl-9-(2-deoxy-3,5-di-O-p-
toluoyl-5-D-erythro-pentofuranosyl)purine (8) ................................61Ammonolysis of Glycosylation Product (6B) ........622-Bromo-0^-p-nitrophenylethyl-2'-deoxyinosine (9) ..........................65Condensation of 0°-NPE-Protected 2-Bromo-2'-
deoxyinosine (9) with Cyclopenta-PAHamino alcohol (7) ..............................68N^-[1-(trans-2-hydroxy-acenaphthenyl)]-0°-p-nitrophenylethyl-2'-deoxyguanosine (10).... 68
IV.  RESULTS AND DISCUSSION .............................75
Synthesis of 0^-NPE-Protected2-Bromohypoxanthine ............................75
Lewis Acid Catalyzed Glycosylation of0°-NPE-Protected 2-Bromohypoxanthine ...........78
Sodium Salt Glycosylation of0^-NPE-Protected 2-Bromohypoxanthine ...........82
Condensation of Glycosylation Product withCyclopenta-PAH amino alcohol ...................85Ammonolysis Reactions on Glycosylation Product ...88
Condensation of 0 -NPE-Protected
2-Bromo-2'-deoxyinosine withCyclopenta-PAH amino alcohol....................97
V.  CONCLUSIONS AND RECOMMENDATIONS ...................100
Summary and Conclusions..........................100"Recommendations for Future Research .............102
REFERENCES ..............................................105
VI
LIST OF TABLES
Table Page
1. Environmental Occurrence of Cyclopenta-PAH...........21
2. PMO Delocalization Energies of Benzylic CarboniumIons Derived from Epoxides of PAH ...................23
3. Physical and Immunological Methods to IdentifyDNA Adducts .........................................27
Vll
LIST OF FIGURES
Figure Page
1. The Multistage Process of Chemical Carcinogenesis ....7
2. Metabolic Activation of a Polycyclic AromaticHydrocarbon .........................................15
3. Structures of Some Cyclopenta-PAH Studied forGenotoxic Activity ..................................20
4. -^^P-Postlabeling of DNA Adducts .....................29
5. Possible Structures of Aceanthrylene-DeoxyguanosineAdducts .............................................33
6. Use of DNA Adducts in Hximan Biomonitoring ...........37
7. Reaction Scheme I ...................................43
8. Reaction Scheme II ..................................44
9. ͣ'•H NMR Spectrum (400 MHz, CDCI3) of Tritylated2-Bromo-0°-p-nitrophenylethylpurine (3),N^ isomer ...........................................50
10. •' ͣH NMR Spectrum (400 MHz, DMSO-dg) of 2-Bromo-O^-p-nitrophenylethylpurine (4) ........................51
^H NMR Spectrum (400 MHz, CDCI3) of N-9 a and 6anomeric mixture of 2-Bromo-0°-p-nitrophenylethyl-11. " -p-nitrophenylethyl-
9-(2-deoxy-3,5-di-O-acetvl-B-D-erythro-pentofuranosyl)purine (6A) ..........................54
12. ^H NMR Spectrum (400 MHz, CDCI3) of 2-Deoxy-3,5-di-O-p-toluoyl-g-D-erythro-pentofuranosylchloride (SB) .......................................56
13. ^H NMR Spectrum (400 MHz, CDCI3) of 2-Bromo-O^-p-nitrophenylethyl-9-(2-deoxy-3,5-di-0-p-toluoyl-6-D-erythro-pentofuranosyl)purine (6B) ................58
14. FAB Mass Spectrum of 2-Bromo-O^-p-nitrophenylethyl-9-(2-deoxv-3.5-di-0-p-toluoyl-B-D-erythro-pentofuranosy1)purine (6B) ..........................59
15. ^H NMR Spectrum (400 MHz, CDCI3) of 2-Bromo-O^-p-nitrophenylethyl-7-(2-deoxy-3,5-di-O-p-toluoyl-B-D-erythro-pentofuranosyl)purine .....................60
Vlll
16. UV-Visible Spectrum (methanol) of FractionContaining N'^-[l-(trans-2-hydroxy-acenaphthenyl) ]-0°-p-nitrophenylethyl-9-(2-deoxy-3,5-di-0-p-toluoyl-B-D-erythro-pentofuranosyl)purine (8) .......63
17. FAB Mass Spectrum of N^-[l-(trans-2-hydroxy-acenaphthenyl)]-0°-p-nitrophenylethyl-9-(2-deoxy-3,5-di-O-p-toluoyl-fi-D-erythro-pentofuranosvl)purine (8) ..........................................64
18. ^H NMR Spectrum (400 MHz, DMSO-dg) of 2-Bromo-O^-p-nitrophenylethyl-2'-deoxyinosine (9) ..............66
19. FAB Mass Spectrum of 2-Bromo-O^-p-nitrophenylethyl-2'-deoxyinosine (9) .................................67
20. UV-Visible Spectrum (methanol) of Fraction PossiblyContaining N -[l-(trans-2-hydroxy-acenaphthenyl)]-
0 -p-nitrophenylethyl-2'-deoxyguanosine (10),after 1st HPLC ......................................70
21. -^H NMR Spectrum (4 00 MHz, CD3OD) of FractionPossibly Containing N^-[l-(trans-2-hydroxy-acenaphthenyl)]-0°-p-nitrophenylethyl-2'-deoxyguanosine (10), after 1st HPLC .................71
22. UV-Visible Spectrum (methanol) of FractionPossibly Containing N^-[l-(trans-2-hydroxy-acenaphtheny1)]-0°-p-nitrophenylethyl-2'-deoxyguanosine (10), after 2nd HPLC .................73
23. Partial ^H NMR Spectrum (500 MHz, DMSO-dg) ofFraction Possibly Containing N^-[l-(trans-2-hydroxy-acenaphthenyl)]-0^-p-nitrophenylethyl-2'-deoxyguanosine (10), after 2nd HPLC ..............74
24. Reaction Mechanism of Lewis Acid CatalyzedGlycosylation .......................................80
25. ^H NMR Spectrum (400 MHz, DMSO-de) of Side-Productin Ammonolysis Rxn - Possibly 2-Bromo-2'-deoxyadenosine ......................................90
26. ^H NMR Spectrum (400 MHz, DMSO-dg) of Side-Productin Ammonolysis Rxn - Possibly a 2-Bromo-2'-deoxyadenosine Derivative ...........................92
27. Mass Spectrum (EI Mode) of Side-Product inAmmonolysis Rxn - p-Nitrophenylethanol ..............94
28. ^H NMR Spectrum (400 MHz, DMSO-dg) of Side-Productin Ammonolysis Rxn - p-Nitrophenylethanol ...........95
CHAPTER I
INTRODUCTION
Covalent interaction of chemical carcinogens with
critical cellular macromolecules, especially DNA, is a key
event in the overall mechanism of chemical carcinogenesis,
and irreversible chemical lesions formed can initiate the
carcinogenic process (Holbrook 1980; Miller and Miller 1981;
Harris 1985; Williams and Weisburger 1986; Hermo 1987).
Ultimate reactive and carcinogenic forms of chemicals
contain an electrophilic atom capable of covalently reacting
with an available nucleophilic atom of a cellular
macromolecule, such as a DNA base, to form a DNA adduct
(Miller and Miller 1981; Dipple, Michejda, and Weisburger
1985).  Most organic genotoxic chemicals, including
polycyclic aromatic hydrocarbons (PAH) and cyclopenta-PAH
(CP-PAH), must undergo metabolic activation (also termed
bioactivation) by cytochrome P-450 dependent mixed-function
oxidases to form the electrophilic reactive intermediates
(Holbrook 1980; Williams and Weisburger 1986).
Numerous studies conducted on alternant PAH, especially
with benzo[a]pyrene, have determined that epoxides and
dihydrodiol epoxides (especially the bay region diol-
epoxide) are the reactive metabolites responsible for
chemical modification of DNA and genotoxicity (see review by
Wislocki and Lu 1988).  Formed by opening of the oxirane
ring, carbonium ions of PAH exhibit strong regioselectivity
for the exocyclic amino groups of guanine (the N-2 position)
and adenine (the N-6 position) (Holbrook 1980; Jeffrey 1985;
Swenberg et al. 1990).
Cyclopenta-PAH, nonalternant PAH that contain a
cyclopenta ring fused to the periphery of an alternant
aromatic nucleus, possess unique structures that can provide
important insight into structure-activity relationships,
especially the effects of molecular geometry and electronic
structure on mutagenic/carcinogenic activity.  Many CP-PAH
are environmental contaminants formed by incomplete
combustion of fossil fuels (Nesnow et al. 1986).
Cyclopenta-PAH have been the focus of many recent
investigations (see review by Gold, Sangaiah, and Nesnow
1988), and it has been determined that cyclopenta-ring
oxidation and (if applicable) bay region diol-epoxide
formation represent major pathways of metabolic activation
for CP-PAH.  A derivative of acenaphthylene, the smallest
CP-PAH, will be utilized in this study to synthesize a
deoxyguanosine adduct of a cyclopenta-PAH.
Identification and quantitation of DNA adducts in
animal and human tissues, in vitro and in vivo, has become
an important expanding area of research.  Detection and
analysis of DNA adducts can aid in formulation of the
following:  stucture-activity relationships for
mutagens/carcinogens especially in predicting genotoxic
activity of new compounds; relationships between DNA adduct
formation and chemical carcinogenesis - hence, cancer risk
in human populations; and relationships between levels of
DNA adducts and environmental chemical exposures - hence,
usefulness of DNA adducts in human biomonitoring as markers
of "biologically effective dose" and as "internal
dosimeters" (Wogan and Gorelick 1985; Harris 1985) of
exposure to genotoxic chemicals.
Of the various immunological and physicochemical
methods available to detect DNA adducts, the highly
sensitive ^^P-postlabeling assay is well suited for aromatic
adducts, and it generates autoradiograms useful as
fingerprint maps for identification of unknown chemicals and
mixtures (see review by Watson 1987).
Using -^^P-postlabeling techniques, partial structural
elucidation of DNA adducts (base/metabolite composition) has
been accomplished by comparing autoradiograms from DNA of
C3H10T1/2 cells exposed to CP-PAH with autoradiograms from
homo oligodeoxynucleotides treated with chemically
synthesized ultimate active metabolites of CP-PAH (Nesnow et
al. 1989; Lasley et al. 1990).  For detailed structural
characterization of adducts, co-chromatography of chemical
synthetic standards of known structure (modified
deoxynucleosides/deoxynucleotides) with cellular adducts is
necessary.  This type of identification procedure has been
reported in the literature for styrene oxide-DNA adducts
(Pongracz et al. 1989).  Detailed structural elucidation of
DNA adducts, which will identify specific sites of attack on
the DNA bases, will provide valuable information at the
molecular level about the initial interactions between
op
chemical mutagens/carcinogens and DNA.  Based on -' ͣ'p-
postlabeling results for aceanthrylene (Nesnow et al. 1989)
and benz(j)aceanthrylene (Lasley et al. 1990) and the
documented regioselectivity of PAH towards the exocyclic
amino group of guanine, initial synthetic targets should be
cyclopenta ring and bay region diol-epoxide adducts at N^ of
deoxyguanosine.
Cyclopenta-PAH amino alcohols of acenaphthylene and
aceanthrylene have been successfully synthesized and used to
generate N-6 adenosine adducts (RNA adducts) expected from
attack of the corresponding ring-opened cyclopenta epoxides
(Bartczak et al. 1989).  Later these amino alcohol
derivatives were successfully condensed with 6-chloropurine-
9-(2-deoxy-fi-D-ribose) to produce N°-deoxyadenosine adducts
(DNA adducts).  Although N^-aryl and N^-alkyl 2'-
deoxyguanosine derivatives have been reported in the
literature (Wright and Dudycz 1984; Casale and McLaughlins
1990; Lee et al. 1990; Hildebrand et al. 1990), no N^-
deoxyguanosine adduct of a cyclopenta-PAH has been
synthesized.
Thus, this pilot study was undertaken to develop
synthetic routes for synthesis of N^-modified deoxyguanosine
using the CP-PAH amino alcohol derivatives previously
prepared, specifically trans acenaphthene l-amino-2-ol.  The
appropriate halopurine precursor to an N -deoxyguanosine
adduct is a 2-halo-2'-deoxyinosine; however, purine
derivatives of this type are not commercially available.
Specific objectives of this study included the following:
1) Develop a straightforward synthetic route for generation
of 2-bromo-2'-deoxyinosine (2-BrdI) or a suitably protected
derivative.  This was to be accomplished by:
A) Synthesis of a protected 2-bromohypoxanthine
derivative.
B) Glycosylation of above compound with some derivative
of 2'-deoxyribose with the objective of obtaining
the N-9 ^-substituted isomer as predominant,
isolable glycosylation product.
2) Test applicability of 2-bromo-2'-deoxyinosine or a
derivative as a precursor to N -deoxyguanosine adducts of a
cyclopenta-PAH by using it to synthesize a (protected) N^-
modified deoxyguanosine:
A) Carry out condensation reaction(s) between 2-BrdI or
its derivative and trans acenaphthene l-amino-2-ol,
3) Evaluate results of the synthetic strategy employed in
this pilot study and make recommendations that will
facilitate the future synthesis of biologically significant
CP-PAH - deoxyguanosine adducts in quantity for eventual
application as chromatographic standards in the -^^p.
postlabeling assay.
CHAPTER II
LITERATURE REVIEW
General Mechanism of Chemical Carcinogenesis
Environmental factors, including certain radiations,
specific viruses, some chemicals, and combinations of the
above, play a strong role in determining the occurrence of
many human cancers (Miller and Miller 1981).  Of the six
million or so chemical compounds which have been identified
and catalogued, about 35 have been recognized by the
International Agency for Reseach on Cancer (lARC) to be
causally associated with increased risk of human cancer
(lARC 1987).  Despite the limited number of compounds which
are recognized as human carcinogens, the list can be
expanded if animal test data is included.  Also, many more
chemical compounds have been found to transform or mutate
cells in culture.
Currently, it is well accepted that chemical
carcinogenesis is a complex multistage process involving
initiation, promotion (including tumor conversion), and
progression, as shown in figure 1 (Holbrook 1980; Miller and
Miller 1981; Harris 1985; Williams and Weisburger 1986;
Hermo 1987).  Chemicals play key roles as initiating
carcinogens and promoting agents in this scheme.
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Fig.   1.     The  Multistage  Process   of  ChemicalCarcinogenesis.     Top,   from  Harris   1985,p.   186;   Bottom,   from  Miller   and  Miller
1981,   p.   2338.
macromolecules leading to covalent adducts, especially of
DNA, is a significant event in the overall mechanism of
chemical carcinogenesis, and irreversible chemical lesions
formed can initiate the carcinogenic process.  Such genetic
events followed by cell proliferation may lead ultimately to
the induction of neoplasia, a process that can span twenty
years or longer in humans.
Hermo (1987) describes the series of events that are
generally referred to as "initiation".  These include:
(1) absorption, distribution, and possible biotransformation
(metabolic activation) of a chemical; (2) interaction of an
electrophilic ultimate carcinogenic metabolite with cellular
macromolecules, particularly DNA (but also RNA/proteins);
and (3) the fixation of carcinogen damage through cell
replication producing a permanent genetic change.
The ability of chemical carcinogens to covalently bind
to and damage DNA can lead to cellular mutational events,
such as point mutations and frame-shift mutations, as well
as other types of gross structural DNA alterations like gene
rearrangement and amplification (Hermo 1987).  Codon
rearrangement may involve sequences known as oncogenes, and
several mechanisms, including point mutation, have been
identified as being responsible for the activation of
cellular proto-oncogenes (Williams and Weisburger 1986).
Gene products of many oncogenes function in biochemical
processes that could be involved in malignant cell
transformation (Marx 1989).
Thus, carcinogen-DNA adduct formation can produce a
permanantly altered or "initiatied" cell (also known as a
latent preneoplastic cell) which may, in the future, undergo
cell divisions and changes in gene expression ultimately
leading to production of a neoplasm.
The "promotion" stage of carcinogenesis involves the
conversion of an initiated precancerous cell to the
transformed neoplastic state then capable of proliferation
leading to clonal amplification and malignant tumor
formation (Hermo 1987).  Cells that have undergone
neoplastic conversion may remain dormant, held in check by
tissue homeostatic factors, but their proliferation may be
facilitated by various chemical promoting agents, such as
phorbol esters (Williams and Weisburger 1986).  Harris
(1985) mentions the concept of tumor conversion, whereby
benign tumors can convert to malignant tumors, and he
suggests that DNA-damaging and mutagenic chemical agents may
cause an additional genetic event that hastens this
conversion.
Many of the specific steps in chemical carcinogenesis,
such as bioactivation and DNA repair, are controlled and
modified by endogenous and exogenous host factors including:
species; sex; age; and immunological, hormonal, and
nutritional conditions (Williams and Weisburger 1986).
Besides the genetic mechanism described above, there is
an alternative, perhaps accompanying, mechanism for
permanent neoplastic conversion that involves epigenetic
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effects on gene expression, possibly stemming from
carcinogenic interaction with proteins and/or RNA (Holbrook
1980; Williams and Weisburger 1986).  As discussed by
Williams and Weisburger (1986), this has led to the
attempted classification of chemical carcinogens as
genotoxic if they interact with and alter DNA or as
epigenetic if a biologic effect other than reaction with DNA
could be the basis for their carcinogenicity.
Metabolism of Xenobiotics in Relation to
DNA Adduct Formation
Many studies on a variety of chemical carcinogens have
shown that their ultimate reactive and carcinogenic forms
contain an electrophilic (relatively electron-deficient)
atom capable of reacting nonenzymatically by covalent bond
formation with an available nucleophilic (electron-rich)
atom of a critical cellular macromolecule (DNA, RNA, and/or
protein) (Miller and Miller 1981; Dipple, Michejda, and
Weisburger 1985).  Direct-acting or primary genotoxic
carcinogens contain intrinsically electrophilic centers and
do not require metabolic activation.  They include such
chemicals as:  alkyl imines, lactones, alkylene epoxides,
sulfate esters, mustards, halo ethers, and certain
nitrosamides (Holbrook 1980; Williams and Weisburger 1986).
In contrast, most organic genotoxic carcinogens are
indirect-acting or secondary carcinogens.  They are not
reactive as the parent compound (termed "pro-" or
"precarcinogen") and must undergo enzymatic metabolic
nactivation (or bioactivation) to the reactive electrophilic
"ultimate carcinogen" (Holbrook 1980; Hermo 1987).  The term
"proximate carcinogen" applies to any intermediate species
involved in the overall metabolic activation.  Indirect-
acting chemicals include:  polycyclic aromatic hydrocarbons,
aromatic amines, quinolines, nitrofurans, nitrosamines, azo
compounds, and more (Williams and Weisburger 1986).
The enzymes necessary for metabolic activation of
xenobiotics (chemicals entering an organism from the
external environment) are concentrated primarily in the
endoplasmic reticulum of hepatocytes.  The primary role of
these systems is the biotransformation and detoxication of
lipophilic compounds to more water-soluble hydrophilic
species which can be more readily excreted from the
organism.  Sipes and Gandolfi (1986) and Singer and
Grunberger (1983) discuss the role of hepatic systems with
particular regard to activation of promutagens and
procarcinogens.
The enzyme-dependent reactions are divided into two
stages:  Phase I, such as oxidation, reduction, and
hydrolysis reactions in which substrates are functionalized
to increase hydrophilicity; and Phase II conjugation
reactions in which a highly polar endogenous group is added
to the hydrophilic site generated by Phase I action.  Of
most importance in metabolic activation are the Phase I
oxidative enzymes in the cytochrome P-450 system, otherwise
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known as the mixed function oxygenase (MFO) system,
monooxygenases, or mixed-function oxidases.
For example, in the case of polycyclic aromatic
hydrocarbons or olefinic compounds, one oxidation pathway
involves the cytochrome P-450-mediated addition of oxygen to
the carbon-carbon double bond to produce an epoxide.
Containing a highly strained 3-membered ring, epoxides are
very reactive intermediates capable of opening to an
electrophilic carbonium ion which can form covalent adducts
with cellular nucleophiles including the DNA bases.  Epoxide
hydrolase (formerly epoxide hydrase/hydratase) is an
important hydrolytic enzyme that can deactivate epoxides by
catalyzing the hydration of arene oxides and aliphatic
epoxides to their corresponding trans-dihydrodiols, which
can be conjugated and excreted.  Some aromatic
dihydrodiols, however, can undergo secondary metabolism by
the MFO enzymes, giving diol-epoxides which may be potent
mutagens and carcinogens.  This pathway has been identified
as the major activation route of benzo[a]pyrene.
Thus, the same enzymes that biotransform and detoxify
xenobiotics to protect the body can also produce reactive
intermediates (including proximate and ultimate carcinogens)
which are inherently capable of causing more harm than the
original parent chemical compound that entered the body.
The balance between rates of formation and rates of
detoxication of these reactive metabolites is important in
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determining whether adverse cellular events might later
occur.
Metabolic Activation of Alternant PAH
Polycyclic (or polynuclear) aromatic hydrocarbons (PAH)
are ubiquitous environmental pollutants formed from the
incomplete combustion of fossil fuels and have been
identified in gasoline and diesel fuel exhaust, coke oven
emissions, coal soot, coal tar and its pitches, mineral
oils, tobacco smoke, and charred food.  As potential
mutagens, carcinogens, and teratogens, PAH pose human health
hazards due to public exposure to these compounds through
inhalation of contaminated air or consumption of certain
food products (Sawicki 1985; Boulos and von Smolinski 1986).
During the past two decades, the most commonly and
extensively studied subset of PAH has been the "alternant"
structures composed of fused aromatic 6-meinbered rings.
"Nonalternant" PAH such as cyclopenta-PAH are characterized
by a cyclopenta ring fused to the periphery of an alternant
aromatic nucleus.  They possess unique structures that can
provide important insight into structure-activity
relationships.  In order to understand the metabolic
activation pathways of cyclopenta-PAH, it is important to
consider the results of previous studies on alternant PAH,
especially those supporting the role of epoxides and diol-
epoxides as the reactive metabolites responsible for
chemical modification of DNA and genotoxicity.
Ih
As described by Dipple, Michejda, and Weisburger (1985)
and shown in figure 2(A), oxidation of a PAH double bond
catalyzed by the cytochrome P-450-dependent arylhydrocarbon
hydroxylases (AHH) can produce an arene oxide.  There are
three known possible outcomes for this initially formed
epoxide:  nonenzymatic rearrangement to a phenol; hydration
catalyzed by the epoxide hydrolase enzyme to a trans-
dihydrodiol; or glutathione conjugation catalyzed by the
glutathione-S-transferases leading to mercapturic acid
excretion products.  One of these three routes can usually
inactivate most primary epoxide metabolites of PAH, offering
no chance for epoxide ring opening to a benzylic carbonium
ion capable of reacting with critical cellular
macromolecules.
For many years the simple "K-region" expoxide was
proposed as the metabolically formed DNA-reactive metabolite
and the ultimate carcinogen of many PAH.  Beginning in the
1970s, numerous studies on the metabolic activation of PAH
focused on benzo[a]pyrene, abbreviated B[a]P (see review by
Wislocki and Lu 1988).  These investigations led to the
discovery of the vicinal dihydrodiol epoxide as the ultimate
carcinogen, formed by further enzyme-dependent oxidation of
the isolated double bond adjacent to a trans-dihydrodiol.
Most of the biologically active diol-epoxides were formed on
a 3-sided peripheral indentation called the "bay region".
Figure 2(B) outlines the metabolic reaction scheme for a PAH
from the parent compound through the dihydrodiol as the
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Fig. 2. Metabolic Activation of a Polycyclic AromaticHydrocarbon.  (A), Disposition of an Epoxide(from Dipple, Michejda, and Weisburger 1985,p. 227); (B), Formation of a Bay Region Diol-Epoxide, (same ref.,p. 274); (C), Stereoisomers
from Metabolism of 3 (a )P (same ref., p. 275);(D), DNA Adduct of B (a )P (from Hermo 1987, p.10),
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proximate carcinogen to the bay region diol-epoxide as the
ultimate carcinogen.
As discussed by Grover (1982), the metabolic conversion
of dihydrodiols to diol-epoxides may depend on whether the
conformation of the dihydrodiol hydroxyl groups is diaxial
(approximately perpendicular to the plane of the molecule)
or diequatorial (approximately within the same plane as the
plane of the molecule).  When the diol groups are adjacent
to a bay in the molecule or an alkyl substituent, they may
be forced to adopt a quasi-diaxial conformation.  In this
conformation further metabolism to the diol-epoxide does not
readily occur possibly because of stereochemical effects
preventing the enzyme-substrate interaction.  However, when
an unhindered dihyrodiol adopts the quasi-diequatorial
conformation, as it does for the precursor to the bay region
diol-epoxide in which the epoxide is adjacent to the bay,
further oxidative metabolism can and does take place.
According to in vitro studies, bay region diol-epoxides
can be converted to glutathione conjugates but do not act as
substrates for epoxide hydrolase, an important factor in
determining their mutagenic and carcinogenic capabilities
(Grover 1982? Dipple, Michejda, and Weisburger 1985).
There are four possible stereochemical isomers of the
bay region diol-epoxides for benzo[a]pyrene (see figure
2(C)), all of which have been chemically prepared.  Use of
these isomeric derivatives as reference compounds has shown
that both metabolic formation and reaction with DNA and
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biological activity are highly stereoselective with
(+)-anti-7.8-dihydrodiol-9,10-epoxide determined to be the
most carcinogenic ultimate species (Jeffrey 1985; Dipple,
Michejda, and Weisburger 1985; Wislocki and Lu 1988).
Figure 2(D) shows the structure of the trans B[a]P-DNA
adduct expected upon epoxide ring opening of the ultimate
carcinogenic species to form an electrophilic carbonium ion
at C-10 that covalently binds to the exocyclic amino group
of deoxyguanosine.  Because of the high stability of the
C-10 carbonium ion, a mixture of cis and trans adducts would
be predicted, but the trans isomer represents greater than
90% of the DNA adducts (Jeffrey 1985) .
In 1976, Jerina et al. proposed the "bay region theory"
to explain the high biological activity of bay region diol-
epoxides (see reviews by Wood et al. 1979; Lehr et al. 1982;
Jeffrey 1985; and Wislocki and Lu 1988).  The concept
postulates that epoxides situated on saturated, angular
benzo-rings located in the bay region of a PAH (bay region
diol-epoxides) should be highly reactive due to greater ease
of electrophilic carbonium ion formation.  This prediction
is based upon Dewar perturbational molecular orbital (PMO)
calculations which estimate resonance stabilization energies
( A E(jeloc /^ values) of benzylic carbonium ions formed upon
ring opening of the epoxides.  Based upon studies on
alternant bay-region PAH, larger values of AEdeloc /^
correspond to greater stabilization of the oxirane ring-
opened carbocation and, in general, to greater biological
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activity of the metabolite with a value of A E(jeloc /^ ^ °''7
determined to be a possible threshold for carcinogenic
activity (Jerina et al. 1976; Wood et al. 1979; Lehr et al.
1982) .
Besides B[a]P, the bay region diol-epoxides of other
PAH including benz[a]anthracene, dibenz[a,h]anthracene,
7,12-dimethyIbenz[a]anthracene, and 3-methyIcholanthrene
have proven to be the most chemically reactive forms,
exhibiting higher mutagenic/carcinogenic activity than
metabolites at non-bay region molecular sites (Grover 1982;
Singer and Grunberger 1983).
The bay region theory predicts chemical reactivities of
the highly stabilized oxirane ring-opened benzylic carbonium
ions formed from bay region diol-epoxides solely on the
basis of perturbational delocalization energies.  It does
not account for regioselectivity of metabolism,
stereochemical, conformational, and/or structural parameters
(like molecular size), which can all influence the
interaction of the reactive intermediate species with
critical cellular nucleophiles.
Metabolic Activation of Cyclopenta-PAH
Cyclopenta-polycyclic aromatic hydrocarbons (CP-PAH)
are characterized by the fusion of an ethylene fragment to
an alternant PAH molecule to form a new PAH containing an
unsaturated five-membered ring (Nesnow et al. 1986).  This
unique class of nonalternant PAH offers further
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opportunities to investigate the roles of molecular
geometry, stereochemistry, and electronic structure in
mutagenic and carcinogenic activity, especially for
comparison with predictions based upon previous studies of
alternant PAH.  In the past decade CP-PAH studies have
focused on the importance of cyclopenta ring and bay region
(if present) features in the mixed-function oxidase
activation of these compounds as well as the correlation of
PMO resonance stabilization energy ( AE^jeioc /B)
calculations with biological activity (see reviews by Nesnow
et al. 1986; Gold, Sangaiah, and Nesnow 1988).
Figure 3 depicts the molecular structures, names, and
common abbreviations of eight cyclopenta-PAH which have been
well studied for genotoxic activity.  Of these CP-PAH, at
least five have been identified as environmental
contaminants primarily from combustion processes, as
indicated in table 1.  The smallest cyclopenta-PAH,
acenaphthylene, contains three rings and is also an
environmental contaminant but is not a bacterial mutagen
(Kaden, Kites, and Thilly 1979).
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Fig. 3. Structures of Some Cyclopenta-PAH
Studied for Genotoxic Activity,
(modified from Nesnow et al. 1986, p. 516)
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Table 1. — Environmental Occurrence of Cyclopenta-PAH
Parent PAH CP-PAH Sources
Pyrene
Phenanthrene
Benz[a]anthracene
CPP
AP
B[e]A
B[j]A
B[1]A
Automobile exhausts
Coal combustion
Wood combustion
Tobacco smoke
Carbon black
Pitch
Grilled foods
Coal combustion
Kerosene combustion
Wood smoke
Tobacco smoke
Carbon black
Coal combustion
Coal combustion
Wood smoke
Source:  modified from Nesnow et al. 1986, p. 517; Krishnan
and Kites 1981, p. 342.
In 1980 Fu, Beland, and Yang presented PMO calculations
on the presumed ultimate carcinogenic metabolites, the
cyclopenta-PAH epoxides, for over fifty CP-PAH compounds.
They reported that the olefinic double bond of the fused
five-membered ring in most CP-PAH has the highest bond order
making it highly susceptible to epoxidation and that the
benzylic carbonium ion resulting from ring opening of the
cyclopenta epoxide may be effectively stabilized by the
aromatic system.  In fact, 33 of the CP-PAH epoxides can
yield carbonium ion intermediates having higher resonance
stabilization/delocalization energies (AEdeloc /^) than
that of the mutagenic and carcinogenic bay region diol-
epoxide of B[a]P (7,8-dihYdrodiol-9,10-epoxide; AEdeloc /^
= 0.794). Fu and co-workers (1980) proposed that some
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cyclopenta-PAHs may present a mutagenic and/or carcinogenic
hazard similar to the classic alternant PAH since the five-
membered ring of CP-PAH provides a site for metabolic
activation by mixed-function oxidases.
Around the same time period, Eisenstadt and Gold (1978)
and Gold et al. (1980) reported their studies on the
metabolic activation, mutagenesis, and morphological
transforming capability of the non-bay-region
cyclopenta[cd]pyrene (CPP) and its cyclopenta epoxide, the
3,4-oxide.  They found CPP to be highly mutagenic with rat
liver S9 activation in the Ames assay, CPP 3,4-oxide to be a
direct-acting mutagen in bacterial and mammalian assays, and
both compounds able to transform mammalian cells in culture.
Gold and co-workers suggested that CPP 3,4-oxide might be
the ultimate mutagenic form of the parent CP-PAH, and this
conclusion was further supported by identification of the
dihydrodiol, 3,4-dihyroxy-3,4-dihydro-cyclopenta[cd]pyrene,
as the major metabolite in bacterial and C3H10T1/2 mouse
cells (Gold, Schultz, and Eisenstadt 1979; Nesnow et al.
1981) .
Of six other CP-PAH studied, including aceanthrylene,
acephenanthrylene, B[e]A, B[j]A, B[1]A, and B[k]A, liver
microsomes from Aroclor-1254 induced rats metabolized all
compounds to cyclopenta-ring dihydrodiols, implicating
epoxide intermediates (Sangaiah et al. 1983, 1986; Nesnow et
al. 1984).  Using the same rat liver S9 activation system,
all of the above CP-PAH were found to be mutagenic in the S^
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typhimurium Ames assay (Nesnow et al. 1984; Sangaiah et al.
1983, 1986).  The four cyclopenta-fused isomers of
benz[a]anthracene were also mutagenic in mammalian cells in
culture (Nesnow et al. 1984).
In S. typhimurium the peak mutagenic activity of B[j]A,
B[e]A, and B[1]A occurred at considerably lower S9
concentrations than B[a]P and B[k]A (Nesnow et al. 1984).
Low optimum S9 concentration has been reported previously
for CPP and was interpreted as indicating activation via a
one-step cyclopenta-ring epoxidation as opposed to the
multistep diol-epoxide activation pathway of B[a]P
(Eisenstadt and Gold 1978).
As shown in table 2, the delocalization energies for
oxirane ring-derived carbocations on the cyclopenta rings of
B[j]A, B[e]A, and B[1]A exceed that of the mutagenic and
carcinogenic bay region C-10 carbonium ion of B[a]P-7,8-
dihydrodiol-9,10-epoxide.
Table 2. — PMO Delocalization Energies of BenzylicCarbonium Ions Derived from Epoxides of PAH
Epoxide Carbonivim ion     AEdgioc /^
ACE-l,2-oxide
B[j]A-l,2-oxide
B[e]A-5,6-oxide
B[l]A-l,2-oxide
B[a]P-7,8-diol-9,10-oxide
CPP-3,4-oxide
B[k]A-4,5-oxide
AP-4,5-oxide
Source: modified from Bartczak 1988, p. 80.
C-1 0.931
C-1 0.879
C-5 0.879
C-1 0.833
C-10 0.794
C-3 0.794
C-5 0.722
C-5 0.664
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The cyclopenta-ring arene oxides of B[j]A, B[e]A,
B[1]A, and B[k]A were synthesized and found to be direct-
acting mutagens in the Ames assay with B[k]A oxide the least
potent in agreement with its lower A E^^eioc /^ value
(Bartczak at al. 1987, 1988).  The results of this study
support the hypothesis that the cyclopenta epoxides of the
three benzaceanthrylene isomers B[e]A, B[j]A, and B[1]A are
major contributors to mutagenicity in the Ames assay, but
other metabolic activation pathways may play a role in the
mutagenicity of B[k]A.  They also reaffirm the utility of
the AEjjeloc /^ parameter as a predictor of mutagenic
activity.
Three of the four cyclopenta-benz[a]anthracene isomers
(B[e]A, B[j]A, and B[1]A) were active in morphologically
transforming C3H10T1/2 cells (Mohapatra et al. 1987).  In
this assay B[j]A and B[1]A were metabolized to cyclopenta-
ring dihydrodiols as well as K-region dihydrodiols and the
dihydrodiol precursor to the bay region diol-epoxide as
major metabolite for B[j]A.  These findings suggest that
alternative routes of metabolic activation besides
cyclopenta-ring oxidation, such as K-region or bay region
activation, may be operative in C3H10T1/2 cells.
Recently, the cell transforming activities of B[j]A,
its cyclopenta epoxide, cylcopenta dihydrodiol, 9,10-
dihydrodiol, and bay region diol-epoxide were studied.
Results establish that both cyclopenta-ring epoxidation and
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formation of the bay region diol-epoxide represent major
independent pathways of metabolic activation (Lasley et al.
1990).
Gold, Sangaiah, and Nesnow (1988) provide a detailed
account of many CP-PAH studies including bioassay results,
metabolic characterization, and structure-activity
considerations.
Molecular Sites on DNA Susceptible to Covalent Reactions
The covalent reactions of elctrophilic ultimate
mutagens/carcinogens with susceptible nucleophilic centers
in DNA can lead to a wide variety of DNA adducts.  Which
nucleophilic molecular sites on DNA are attacked depends
upon several factors including the reaction mechanism (as
unimolecular Sjjl or bimolecular Sjj2) , the strength of the
nucleophile, characteristics of the electrophile such as
hardness and stability, and steric constraints (Jeffrey
1985; Swenberg et al. 1990).  The most strongly nucleophilic
sites in DNA involve the ring-nitrogens, particularly N-7 of
guanine, and the more weakly nucleophilic sites include the
oxo and amino groups of the four DNA bases (Holbrook 1980;
Jeffrey 1985; Swenberg et al. 1990).
Alkylating agents, such as methyl methanesulfonate,
that react by the Sn2 mechanism favor the most nucleophilic
sites, like the N-7 position of guanine, in the absence of
steric factors (Holbrook 1980; Jeffrey 1985; Swenberg et al.
1990).  Chemical agents, such as methylnitrosourea, that
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react by the Sfjl mechanism tend to be less selective and
react efficiently at oxygens and other nitrogens in DNA.
This can lead to alkylation on positions such as:  N-1, N-3,
and N-7 of adenine; N-3 and O^ of guanine; N-3 of cytosine;
O^ of thymine; and the hydroxyl of phosphates (Holbrook
1980; Jeffrey 1985; Swenberg et al. 1990).
Proceeding by the Sjjl mechanism, metabolites of
aromatic amines and amides react preferentially with C-8 of
guanine.  N^ of guanine and N^ of adenine are frequent
positions of attack by the stable carbonium ions of
polycyclic aromatic hydrocarbons (Holbrook 1980; Jeffrey
1985; Swenberg et al. 1990).
Adducts formed at several sites that normally
participate in the hydrogen bonding of complementary bases
(such as N-3 of cytosine, O^ of guanine, or O of thymine)
are critical with respect to mutagenesis and carcinogenesis
because they have the potential to induce base mispairing
when DNA is replicated (Holbrook 1980; Hermo 1987; Swenberg
et al. 1990).
Methods of Identification and Quantitation
of DNA Adducts
Detection and characterization of DNA adducts can aid
in the formulation of structure-activity relationships for
mutagens/carcinogens (including stereo- and regioselectivity
factors) and can also help establish relationships between
DNA adducts and exposure to environmental chemicals as well
as initiation of chemical carcinogenesis.  There are
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currently several immunological and physical techniques
available to identify and measure adducts in DNA isolated
from exposed tissues and cells of animals and humans, both
in vitro and in vivo (see table 3).  Wogan and Gorelick
(1985), Farmer, Neumann, and Henschler (1987), and Swenberg
et al. (1990) provide overviews of the various methods.
Table 3. — Physical and Immunological Methods to Identify
DNA Adducts
Assays Sensitivity DNA used
HPLC - fluorescence
detection 1 adduct/10' bases 100 ugHPLC - UV 2 adducts/10^ bases 2600 ug
Synchronous fluorescencespectrophotometry(SFS)  1 adduct/10^ bases ---Radioimmunoassay(RIA)     1 adduct/10^ bases 1 ug
Enzyme radioimmunoassay(competitive USERIA)   1 adduct/10^~^ bases 25 ugͣ^^P-postlabeling 1 adduct/10^ -' ͣ'^bases 1 ug
1 adduct/diploid mammalian genome = 1 / 1.2 X 10 bases
Source:  modified from Wogan and Gorelick 1985, p. 12;
Farmer, Neumann, and Henschler 1987, p. 256.
Much knowledge on the interactions between carcinogens
and DNA has been obtained by the reaction of radiolabeled
chemicals with DNA or their administration to cells or
animals followed by separation, quantification, and
identification of the adducts.  However, this approach is
limited by the small number of compounds available in
radiolabeled form, the high cost of synthesis, the rather
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"large" amounts (up to mg) of DNA required for analysis, and
inapplicability to studies in humans.
High pressure liquid chromatography (HPLC) in
conjunction with UV or fluorescence detection has been
employed for detection of B[a]P-DNA adducts.  Synchronous
fluorescence spectrophotometry (SFS) can be useful for
carcinogens that fluoresce, like PAH and aflatoxins, and may
be suitable for complex mixtures as contour maps of spectra
become available.
Monoclonal and polyclonal antibodies, which have been
prepared against a variety of specific carcinogen-DNA
adducts, can be used in specific and sensitive immunological
techniques which have applications to human tissue samples.
These competitive or noncompetitive immunoassays include the
radioimmunoassay (RIA), enzyme-linked immunosorbent assay
(ELISA), and ultrasensitive enzymatic radioimmunoassay
(USERIA).
The •^^P-postlabeling techniques can successfully detect
adducts of aromatic amines and amides, PAH, and methylating
agents.  Sensitivity of this assay is, in theory, the
highest available to date for aromatic or bulky adducts.
•^^P-Postlabeling Techniques
In 1981 Randerath, Reddy, and Gupta reported a -^^p.
postlabeling method for the detection and quantitation of
covalent adducts formed by the reaction of DNA with chemical
carcinogens and mutagens.  As depicted in figure 4, the
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basic procedure involves enzymatic digestion of isolated DNA
to deoxynucleoside 3'-monophosphates which are then
converted to their corresponding S'-'^^P-labeled 3',5'-
biphosphates by T4 polynucleotide kmase-catalyzed  P
transfer from adenosine CY--^^P]triphosphate.  The mixture of
labeled adducts is then purified and resolved by four-
directional thin layer chromatography, usually anion
exchange TLC on polyethyleneimine (PEI)-cellulose plates.
Autoradiography is used to determine the presence of
chemically modified nucleoside 3',5'-biphosphates.  Adduct
spots are then cut from the plates and measured using
Cerenkov or liquid scintillation counting.
With the aim of increasing the sensitivity and accuracy
of quantitative measurements, the original techniques were
later modified with adduct enrichment procedures in a
butanol extraction modification (Gupta 1985) and nuclease PI
modification (Reddy and Randerath 1986).  The butanol adduct
enrichment procedure, which involves extraction with 1-
butanol in the presence of the phase-transfer agent
tetrabutylammonium chloride prior to the labeling, is
particularly suited to analysis of aromatic carcinogen-DNA
adducts (especially PAH).  It has been shown to enhance
assay sensitivity to a level of 1 adduct per lo^"-^^
nucleotides with 1-10 ug of DNA used (Gupta 1985; Gupta and
Earley 1988).
Randerath et al. (1985) used the butanol extraction
3?P-postlabelmg technique to determine binding levels of
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individual PAH to mouse skin DNA in vivo, and they observed
a good correlation between carcinogenic potency and binding.
They failed to detect DNA binding of the noncarcinogens
anthracene, pyrene, and perylene while the strong
carcinogens B[a]P, 7,12-dimethylbenz[a]anthracene, and 3-
methylcholanthrene exhibited highest levels of binding.
Watson (1987) and Randerath et al. (1985) review the
significant advantages of the -^^P-postlabeling assay which
include the following features:  it is applicable to
individual chemical compounds and mixtures; chemical
identity of adducts doesn't have to be known to detect DNA
binding; fingerprint patterns obtained after autoradiography
of known chemicals can be used for identification of unknown
chemicals and mixtures; it is highly sensitive for aromatics
enabling detection of a few adducts per mammalian genome; it
requires a minimal amount (1-10 ug) of DNA; it allows
accurate quantitation of adducts; and it is potentially
useful for studying repair and removal of adducts from cell
or tissue DNA.
Application to DNA Adducts of Cyclopenta-PAH.
Recently Nesnow et al. (1989) analyzed and identified
aceanthrylene-DNA adducts in C3H10T1/2 cells by using the
butanol extraction modification of the -^^P-postlabeling
technique.  C3H10T1/2 cells treated with aceanthrylene for
24 hours formed four major adducts which were determined to
be ACE-l,2-oxide-deoxyguanosine adducts (cyclopenta epoxide
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adducts).  Identities of this ACE metabolite and DNA base
portion of the adducts were confirmed by co-chromatography
of adduct mixtures from ACE-treated C3H10T1/2 cells, calf
thymus DNA incubated with ACE-1,2-oxide, and the
homopolymers of 2'-deoxyguanosine modified by ACE with
Aroclor-1254-induced rat liver S9 activation.
Because of the large delocalization energy ( A E^^gioc
/6) associated with the C-1 carbonium ion formed from the
opening of ACE-1,2-oxide (Sangaiah et al. 1986), possible
structures of the ACE-DNA adducts might be isomers of N^-[l-
(trans-2-hydroxy-aceanthrylenyl)]-2'-deoxyguanosine and 0°-
[l-(trans-2-hydroxy-aceanthrylenyl)]-2'-deoxyguanosine, as
shown in figure 5 (Nesnow et al. 1989).
In order to accomplish the detailed structural
characterization of these adducts, co-chromatography with
known chemical synthetic standards is needed.  Results from
this study support the choice of ACE-1,2-oxide-
deoxyguanosine adducts as targets for synthetic standards,
with exocyclic amino group modification given top priority
based on high susceptibility of this nucleophilic position
to covalent reaction with arene oxides.
Benz[j]aceanthrylene adducts in C3H10T1/2 cells have
been studied in a similar manner using the same -^2p_
postlabeling techniques (Lasley et al. 1990).  DNA adduct
autoradiograms were generated after treatment of the cells
with B[j]A-l,2-oxide, B[j]A-9,lO-dihydro-9,10-diol, the
B[j]A bay region anti diol-epoxide, and B[j]A-l,2-dihydro-
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Fig. 5. Possible Structures of Aceanthrylene-
Deoxyguanosine Adducts. (modified from
Nesnow et al. 1989, p. 232).
(A), N -[l-(trans-2-hydroxyaceanthryIenyI)]-2'-deoxyguanosine;
(B), O -[l-(trans-2-hydroxyaceanthrylenyI)]-2'-deoxyguanosine.
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1,2-diol.  These autoradiograms were compared with those
produced by treatment of homo polydeoxyguanylic acid with
B[j]A-1,2-oxide and the B[j]A bay region anti diol-epoxide.
Major adducts were determined to be formed by reaction of
the bay region diol-epoxide with deoxyguanosine with minor
contributions from reaction of B[j]A-1,2-oxide (the
cyclopenta epoxide) with deoxyguanosine.  Synthetic
standards of deoxyguanosine modified at N-2 by the B[j]A
diol-epoxide and B[j]A-1,2-oxide are needed in order to
confirm the structures of these DNA adducts to a higher
degree of specificity than base/metabolite composition.
This type of identification procedure, involving the
use of chromatographic standards in the ^P-postlabeling
assay, has been reported in the literature.  Pongracz et al.
(1989) utilized chemical synthetic standards in the -^^p.
postlabeling assay to identify two of the six DNA adducts
formed by styrene oxide, which corresponded to aralkylation
at 0-6 of guanine.
Use of DNA Adducts in Human Biomonitorinq
Traditionally, human exposure to occupational and
environmental chemicals has been assessed by measuring
concentrations of a substance in ambient environmental media
- air, food, and water.  However, biological monitoring,
measurements that can be made on cells, tissues, or body
fluids of exposed people, is presumably more directly
relevant to the assessment of human health risks than any
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environmental monitoring method (Miller 1984; Wogan and
Gorelick 1985; Farmer, Neumann, and Henschler 1987; Wogan
1989).
Biological monitoring indicates the "internal dose" or
"biologically effective dose" on an individual basis and
takes into account variation in absorption, distribution,
and metabolism of xenobiotics (Wogan and Gorelick 1985;
Wogan 1989; Farmer, Neumann, and Henschler 1987).
Measurements of levels of the parent compound or its
metabolite(s) in body tissues/fluids or excreta (usually
blood, urine, and expired air) provides information on the
"internal dose" of a chemical substance, which reflects
environmental/occupational exposure (Miller 1984; Perera
1987).  "Biologically effective dose" (also known as "target
dose" or "molecular dose") refers to the amount of a
chemical agent (mutagen/carcinogen) or its metabolite
(ultimate carcinogen) that has reacted with critical
cellular macromolecules (DNA, RNA, and/or proteins) of the
target tissue or its surrogate (Perera 1987; Farmer,
Neumann, and Henschler 1987).
For human biological monitoring (or biomonitoring),
markers of biologically effective dose include the
following:  covalently bound DNA adducts, excreted DNA
adducts, protein (i.e. hemoglobin or albumin) adducts,
somatic cell mutations, micronuclei in lymphocytes,
chromosomal aberrations, sister chromatid exchanges,
unscheduled DNA synthesis, and oncogene activation
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(Perera 1987).  Figures 6(A) and 6(B) portray the role of
DNA adduct determination as a biomonitoring technique in the
overall assessment of human exposure to environmental
mutagens/carcinogens.
Wogan and Gorelick (1985) and Harris (1985) discuss the
application of carcinogen-DNA adducts as "internal
dosimeters" of exposure to genotoxic chemicals.  Qualitative
and quantitative identification of DNA adducts in accessible
human tissue (such as white blood cells or biopsy samples)
can provide indication of an individual's exposure history
as well as one's ability to metabolize a mutagen/carcinogen
to its reactive form.  As shown in figure 6(C), many factors
affect the levels of carcinogen-DNA adducts detected in
cells at any given time including the exposure-sampling
interval, carcinogen exposure concentration, the metabolic
balance between carcinogen activation and detoxication, and
DNA repair rates (Harris 1985).
Although information from some experimental animal
models suggests that levels of DNA adducts in tissues are
linearly related to carcinogen dose (Wogan and Gorelick
1985), meaningful interpretation of DNA adduct levels as
quantitative measures of exposure in humans is much more
complex.  This is due to the factors previously discussed as
well as diverse human exposures to chemicals from a variety
of sources beyond the workplace, all of which may influence
adduct levels in a manner not easily determined.  The
ability of carcinogen-DNA adduct levels to accurately
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reflect past or recent chemical exposures (adduct
persistence) and acute or chronic exposures needs to be
extensively investigated.  According to Wogan and Gorelick
(1985) and Harris (1985), DNA adducts can currently serve as
useful qualitative markers of exposure.
Regarding the use of carcinogen-DNA adduct levels as
indicators of long-term cancer risk, further complications
arise including the validity of surrogate cell measurements
in lieu of actual target tissue at risk and the necessary
simplifying assumptions made about the multistage
carcinogenic process (see Harris 1985; Perera 1987; Farmer,
Neumann, and Henschler 1987 for information on DNA adducts
in cancer risk assessment).  Perera (1987) thoroughly
reviews the growing field of molecular cancer epidemiology
which involves conducting studies that establish
relationships between biologic markers of dose and cancer
risk in human populations.
Detection of Aromatic DNA Adducts in Human Tissues bv -^^P-
Postlabeling
Wogan (1989) thoroughly reviews the numerous human
biomonitoring studies that have involved detection of DNA
adducts of genotoxic agents in the cells and tissues of
exposed persons.  In the past, many have focused on
detection of adducts arising from the bay region diol-
epoxide (BPDE) metabolite of B[a]P through immunoassays
,such as ELISA or USERIA, or physicochemical methods like
SFS.  BPDE adducts have been identified in DNA from white
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blood cells of cigarette smokers, foundry workers, aluminum
plant workers, and coke oven workers (see review by Wogan
1989).
Recently, numerous studies, many involving smokers,
have employed the -^^P-postlabeling techniques for the
detection of aromatic DNA adducts in human cells or tissues.
Everson et al. (1986) investigated the presence of DNA
adducts formed in placentas of women who smoked during
pregnancy, and they found a major aromatic adduct strongly
related to maternal smoking.
Through co-chromatography in the postlabeling assay,
Randerath et al. (1986) compared DNA adducts detected in
mouse skin treated with cigarette tar with DNA adducts
detected in tissues from the bronchus and larynx of smokers.
They observed several identical adducts present in the DNA
samples from exposed mice and smokers.
DNA from normal human bone marrow cells was analyzed by
•^^P-postlabeling, and ten out of ten individuals showed the
presence of aromatic adducts that were not detected in human
fetal bone marrow (Phillips, Hewer, and Grover 1986).  Their
findings suggest that adducts reisulted from environmental
exposure to unidentified genotoxic chemicals.
Chacko and Gupta (1987) analyzed DNA from human oral
mucosal cells of smokers and nonsmokers.  Two
chromatographically distinct major adducts were detected in
most smokers but not in nonsmokers.  In addition, they
report the use of known aromatic carcinogen-DNA adducts as
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chromatographic standards to aid in the chemical
identification of the mucosal DNA adducts.  These co-
chromatography experiments eliminated the possibility that
any lesions were formed from reaction of B[a]P with N'' of
guanine or reaction of 4-aminobiphenyl with C-8 of guanine.
Phillips et al. (1987) detected aromatic adducts in DNA
from white blood cells of foundry workers classified
according to their exposure to airborne BCa^P in the
workplace.  Interestingly, none of the detected adducts in
the individuals' DNA showed the chromatographic behavior
expected of B[a]P-DNA adducts, and adduct spots were
detected in a few unexposed workers.  These results indicate
that there may be significant interindividual variations in
DNA adduct levels among similarly exposed workers.
DNA from white blood cells and placentas of non-smoking
women exposed to residential wood combustion smoke during
pregnancy was analyzed by the postlabeling assay for PAH-DNA
adducts (Reddy, Kenny, and Randerath 1987).  All placental
DNA postlabeling maps (from exposed and nonexposed women)
showed the presence of nine unidentified adducts that did
not appear on WBC DNA maps.  Their results suggest that
residential wood combustion smoke did not produce DNA
adducts at detectable levels and that placental DNA
contained DNA adducts unrelated to wood smoke exposure.
CHAPTER III
EXPERIMENTAL MATERIALS AND METHODS
Basis for Synthetic Approach
Trans B-amino alcohol derivatives (enantiomeric
mixtures) of acenaphthylene and aceanthrylene were
previously synthesized and successfully used in condensation
reactions with 6-chloropurine-9-6-D-ribofuranose to give
N°-adenosine adducts, RNA adducts expected from the
corresponding 1,2-oxides (Bartczak et al. 1989).  The same
CP-PAH derivatives were later successfully condensed with
6-chloropurine-9-(2-deoxy-B-D-ribose) to produce N^-
deoxyadenosine adducts (Gold: unpublished results).
For synthesis of N^-modified deoxyguanosine (DNA
adducts), the appropriate halopurine precursor is a 2-halo-
2'-deoxyinosine.  Generation of the 2-chloro derivative had
been attempted previously in this laboratory and was
achieved by Lewis acid catalyzed glycosylation of 2-
chlorohypoxanthine (from partial hydrolysis of 2,6-
dichloropurine) with 2-deoxy-3.5-di-O-p-toluoyl-a-D-erythro-
pentofuranosyl chloride (unpublished results).  However, due
to high cost of 2,6-dichloropurine and presumed increased
efficiency of the condensation reaction expected by the more
reactive bromoinosine derivative, synthesis of 2-bromo-2'-
deoxyinosine was investigated.
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Recently, Hildebrand et al. (1990) indicated use of
2-broino-2'-deoxyinosine (2-BrdI) in generation of N^-n-
hexyl-2'-deoxyguanosine, but no details of the synthesis of
2-BrdI were provided in the literature.  In addition,
although N^-aryl and N^-alkyl 2'-deoxyguanosine derivatives
have been reported in the literature (Wright and Dudycz
1984; Casale and McLaughlin 1990; Lee et al. 1990;
Hildebrand et al. 1990) , no synthesis of N^-itiodified-2'-
deoxyguanosine involving a cyclopenta-PAH has been
published.
Efficient synthesis of 2-bromohypoxanthine (1) has been
reported in the literature (Beaman, Gerster, and Robins
1962).  The Lewis acid catalyzed glycosylation of 2-
bromohypoxanthine with the anomeric mixture 1,3,5-tri-O-
acetyl-2-deoxy-<x. S-D-erythro-pentofuranose (synthesized
according to Gold and Sangaiah 1990) yielded a mixture of N^
a plus 6 and N a plus B isomers which couldn't be readily
separated (Gold: unpublished results).
To avoid problems previously encountered in separating
isomeric glycosylation products and to presumably enhance
yields of N^ isomers over N^ isomers, synthesis of 0°-NPE
(p-nitrophenylethyl group)-protected 2-bromohypoxanthine (4)
by the method of Raju, Robins, and Vaghefi (1989) was
undertaken in this study, as shown in reaction scheme I of
figure 7.  The synthetic strategy was originally based on
Lewis acid catalyzed glycosylation of the NPE-protected 2-
bromohypoxanthine (4) with anomeric 1,3,5-tri-0-acetyl-2-
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deoxy-g.,B-D-erythro-pentofuranose (5A), as shown in figure
7.  However, the synthetic scheme was later modified due to
difficulties in efficiently separating the N^ a and 6
isomeric glycosylation products (6A) .
Thus, reaction scheme II (shown in figure 8) was
developed.  This involved a sodium hydride catalyzed
glycosylation of 0^-NPE-protected 2-bromohypoxanthine (4)
with 2-deoxy-3,5-di-O-p-toluoyl-a-D-erythro-pentofuranosyl
chloride (5B).  The direct glycosylation product (6B) was
then coupled with trans acenaphthene l-amino-2-ol (7) to
generate protected N^-deoxyguanosine adducts (8).
In hopes of improving yields of the final adduct
products, ammonolysis reactions were carried out on the
glycosylation product (6B) to remove the bulky p-toluoyl
groups (giving 0^-NPE-protected 2-BrdI, 9) prior to
condensation with the cyclopenta-PAH derivative.
Condensation reactions were conducted with the NPE group
still intact on the 0-6 position of the purine because the
resulting aromatic 6-membered ring is expected to enhance
the nucleophilic substitution reaction at C-2.
Instrumentation and Laboratory Materials
^H nuclear magnetic resonance (NMR) spectra were
acquired at the UNC Department of Chemistry on a Varian
XL-400 at 400 MHz.  Chemical shifts are given in parts per
million (ppm) relative to tetramethylsilane (TMS).  Mass
spectra were obtained at the UNC Department of Environmental
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Sciences and Engineering on a VG 70S 250SEQ mass
spectrometer using a fast atom bombardment (FAB) source.
UV-visible spectra were recorded on a Spectronic 1201
spectrophotometer (Milton Roy Company).
High performance liquid chromatography (HPLC) was
performed with an ISCO Model 2360 gradient programmer and
2300 pump connected to a DuPont Zorbax C-8 9.4 X 250 mm
column.  Melting points were determined on a Fisher-Johns
apparatus and are uncorrected.  Preparative thin layer
chromatography (TLC) was conducted using Silica Gel PK5F
(20 X 2 0 cm) 500 um/1000 um plates (Whatman) or Reversed
Phase PLKC18F Linear-K (20 X 20 cm) 1000 um plates
(Whatman).  Analytical TLC was performed using Silica Gel on
Aluminum (5 X 10 cm) plates (Aldrich).  Column
chromatography was conducted using Merck Silica Gel, grade
60, 230-400 mesh, 60 A obtained from Aldrich Chemical
Company, Inc.
All solvents were reagent grade, and they were dried
over CaH/P205 and distilled prior to use where indicated.
All routine chemicals were purchased from one of the
following commercial sources:  American Scientific Products
(Charlotte N.C. distribution center); Aldrich Chemical
Company, Inc. (Milwaukee, Wis.); Sigma Chemical Company (St.
Louis, Mo.); and Fisher Scientific (Fair Lawn, N.J.).
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Synthesis of 0°-NPE-Protected 2-Bromohvpoxanthine (4)
2-Bromohypoxanthine was converted to its 0°-NPE-
protected derivative based on the three-step procedure of
Raju, Robins, and Vaghefi (1989) with slight modifications
regarding work-up.  The reaction sequence, shown in figure
7, was repeated twice in order to generate sufficient
amounts of 2-bromo-0°-p-nitrophenylethylpurine for use in
future glycosylation reactions.  Typical reaction procedures
were as follows.
2-Bromohypoxanthine (1)
The starting material (1) was prepared by Dr. Sangaiah
according to the procedures of Beaman (1954) and Beaman,
Gerster, and Robins (1962).  The reaction sequence entailed
purine ring closure of 2-mercapto-4,5-diamino-6-
hydroxypyrimidine to produce 2-mercapto-6-hydroxypurine
followed by replacement of the mercapto group with bromine
to give the bromopurine (l). UV-visible spectrum (ethanol)
of 1 agreed with reported values (Beaman 1954): ^max ~ 252.2
nm, and the structure was confirmed by ^H NMR and FAB MS.
Tritylated 2-Bromohypoxanthine (2)
A mixture of compound 1 (0.5 g, 2.33 mmol), trityl (Tr)
chloride (1.3 g, 4.66 mmol), and dried, distilled
triethylamine (3 mL, 21.5 mmol) was heated at 100'C with
stirring for 2 h.  Triethylamine was removed on a rotary
evaporator under oil pump vacuum at 65"C, and the entire
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sludgy yellow-brown residue containing 2 was carried on to
the next step.
Tritvlated 2-Bromo-O^-p-nitrophenylethvlpurine (3)
To the crude compound 2 from the previous step, was
added 4-nitrophenylethanol (0.78 g, 4.66 mmol),
triphenylphosphine (1.22 g, 4.66 mmol), and diethyl
azodicarboxylate (0.8 mL, 5.1 mmol) in dried, distilled 1,4-
dioxane (15 mL).  The mixture was heated at 80°C with
stirring for 6 h.  To quench the reaction, deionized water
(15 mL) was added with stirring for 5 min.  Dioxane and
water were removed on a rotary evaporator under oil pump
vacuum at 70°C to give a syrupy brown-yellow residue.
Attempted crystallization of 3 from this residue in hot
2-propanol gave a yellow crystalline precipitate, which
contained phenyl-substituted impurities according to ^H NMR
analysis (probably trityl alcohol).  This precipitated
product was purified by column chromatography on silica gel
with benzene:chloroform (1:3) as eluant, gradually increased
to 100% chloroform.  The N-9 isomer of desired product 3
eluted before the N-7 isomer.
Appropriate fractions were combined and solvents
removed on a rotary evaporator and oil pump to afford a
white crystalline solid for the N-9 isomer (280 mg) and a
light yellow crystalline solid for the N-7 isomer (115 mg)
of pure compound 3.  Yield of 3 from 1 was 28%.  ^H NMR
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spectrum (4 00 MHz, CDCI3) of 3 concurred with reported
values from Raju, Robins, and Vaghefi (1989) (see figure 9).
2-Bromo-O^-p-nitrophenylethylpurine (4)
To pure compound 3 from the previous step was added an
8 0% acetic acid solution (20 mL), and the suspension was
heated at SO'C with stirring.  The reaction was monitored by
analytical TLC and stopped at 45 min after 3 had dissolved
in the solution.  Acetic acid and water were removed on a
rotary evaporator under oil pump vacuum at 70°C, and an off-
white crystalline solid was the product.  Trituration (2 X)
of this reaction product with chloroform gave a precipitate,
and the mixture was filtered under vacuum to obtain an off-
white crystalline solid and a light yellow filtrate
solution.
Analytical TLC and ͣ' ͣH NMR analysis (400 MHz, DMSO-dg)
showed that the off-white crystalline precipitate was a
single product, identified as compound 4 (200 mg) by the -^H
NMR spectrum which agreed with published data (Raju, Robins,
and Vaghefi 1989) (see figure 10).  Yield of 4 from 3 was
85%, and the overall yield of 4 from 1 was 24%.  Compound 4
was evacuated on an oil pump at 75°C for 10 h to ensure
complete removal of traces of water prior to proceeding with
a glycosylation reaction.
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Lewis Acid catalyzed Glvcosvlation of 0°-NPE--Protected
2-Bromohvpoxanthine (4)
The Lewis acid catalyzed glycosylation reaction was
carried out according to the conditions of Raju, Robins, and
Vaghefi (1989) with work-up methods taken from Wright and
Dudycz (1984).  The reaction sequence, shown in figure 7,
involved the following procedures.
l,3.5-Tri-0-acetyl-2-deoxy-a,6-D-erYthro-pentofuranose (5A)
The deoxyribose derivative 5A was prepared by Dr. Gold
using a three-step published procedure (Gold and Sangaiah
1990) beginning with 2-deoxy-D-erythro-pentofuranose.  An
^H NMR spectrum (400 MHz, CDCI3) of 5A was taken prior to
use in the glycosylation reaction, and the spectrum
confiirmed its structure and purity in agreement with the
referenced values.
2-Bromo-0^-p-nitrophenylethyl-9-(2-deoxy-3.5-di-O-acetyl-B-D-erythro-pentofuranosyl)purine (6A) and Its Isomers
Under an argon atmosphere, a white suspension of dried
compound 4 (0.34 g, .95 mmol) in dried, distilled
acetonitrile (10 mL) was treated with bistrimethyl-
silylacetamide (BSA) (0.7 mL, 2.84 mmol) and stirred for 1 h
at room temperature, giving a clear yellow solution.  To
this solution was added compound 5A (0.25 g, .95 mmol) in
dried, distilled acetonitrile (5 mL) with stirring followed
by rapid addition of the catalyst TMSOTf (CF3S03SiMe3) (0.3
mL, 1.42 mmol).  After stirring for 15 min, this solution
was refluxed with stirring under argon for 1 h.  The clear
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brown solution was then stirred at room temperature
overnight (16 h).
The acetonitrile was then evaporated at room
temperature on a rotary evaporator under oil pump vacuum
with a dry ice condenser, and the residual yellow syrup was
dissolved in chloroform (50 mL).  The solution was washed
with water until the pH of the aqueous phase was neutral (4
X 25 roL) and then dried over anhydrous sodium sulfate.  The
chloroform was removed on a rotary evaporator at 55°C to
give a light yellow solid product, which was purified by
preparative TLC on silica gel developed with 1% methanol in
chloroform.
The bands containing a mixture of N-9 a and 6 anomers
of 6A (Rf=0.4) gave an off-white crystalline solid (300 mg)
that was subjected to further prep TLC in an attempt to
separate the anomers by using various combinations of
eluants (2% isopropanol in chloroform proving best).
However, complete resolution of the N-9 a and B anomeric
mixture could not be achieved.  The combined yield of N-9 a
and 6 anomeric mixture of 6A was 56% with a ratio of 6
anomer/a anomer of 45% /55%. The ^H NMR (400 MHz, CDCI3)
spectrum (see figure 11) was in accord with expectations for
the mixture of anomers. The salient features were a pseudo-
triplet signal for H-1' of the B anomer and a doublet of
doublets signal for H-1' of the a anomer.
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Sodium Salt Glvcosylation of 0^-NPE-Protected
2-BromohvPOXanthine (4)
The sodium salt (sodium hydride catalyzed)
glycosylation of 4 with chlorofuranose 5B was accomplished
by the method of Kazimierczuk et al. (1984), Wright et al.
(1987), and Kazimierczuk et al. (1990).  The reaction
sequence, shown in figure 8, was repeated twice in order to
generate a sufficient amount of O^,3',5'-protected
derivative of 2-bromo-2'-deoxyinosine (6B) for use in future
condensation reactions.  Typical reaction procedures were as
follows.
2-Deoxv-3.5-di-O-p-toluovl-a-D-erythro-pentofuranosvl
chloride (5B)
The chlorofuranose SB was synthesized exactly in
accordance with the detailed procedures of Zorbach and
Tipson (1968, pp. 521-22) so specifics will not be provided
here.  The three-step sequence involved conversion of 2-
deoxv-D-erythro-pentose to methyl 2-deoxyribose followed by
addition of p-toluoyl groups to 3 and 5 positions and then
the final substitution of chlorine at the 1 (a) position of
the sugar.
9.99 g (70% yield) of 5B was obtained, and its ^H NMR
spectrum (400 MHz, CDCI3) verified its structure and purity
(see figure 12).
2-Bromo-0^-p-nitrophenylethyl-9-f2-deoxy-3.5-di-O-p-toluoyl-fi-D-ervthro-pentofuranosyl)purine (6B) and Its 7-B Isomer
Under an argon atmosphere, sodium hydride powder (97%)
was added to a stirred suspension of dried compound 4
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Fig. 12. ^H NMR Spectrum (400 MHz, CDCI3) of 2-Deoxy-3,5-di-O-p-toluovl-^-D-ervthrQ-
pentofuranosyl chloride (5B)
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(0.48 g, 1.32 mmol) in dried, distilled acetonitrile (20
mL), and the mixture was stirred for 3 0 min.  Next, compound
5B was added in small portions over a 20 min period, and the
cloudy mixture was stoppered and stirred overnight (16 h) at
room temperature under an argon atmosphere.
The reaction mixture was filtered under vacuum using a
sintered glass fine frit to remove a tan crystalline solid
precipitate (95 mg).  The acetonitrile was removed from the
clear light yellow filtrate on a rotary evaporator at 80°C
followed by further evacuation under oil pump vacuum for
complete drying.  The resulting light yellow solid product
was purified by column chromatography on silica gel with 4%
acetone in toluene as the initial eluant.  After the N-9 B
glycosylation isomer 6B eluted, 6% acetone in toluene was
used to elute the N-7 6 isomer of 6B that followed.
Appropriate fractions were combined and solvents
evaporated on a rotary evaporator and oil pump to afford a
pure off-white crystalline solid for the N-9 6 isomer (368
mg, 39% yield) and a pure off-white crystalline solid (508
mg) for the N-7 6 isomer.
For the N-9 6 glycosylation isomer 6B:   Melting point
82-84°C.  ^H NMR (400 MHz, CDCI3) (see figure 13) -6 2.41,
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(IH, s, H8).  FAB Mass Spectrum (see figure 14) - m/z
716,718 (MH)"*"; 638 (MH-Br)"^; 363,365 (MH-dR)"^; Accurate Mass
of MH"*" - observed 716.1361, 0.9 ppm difference from
calculated value for C34H3o08N5'^^Bri+H  716.1354.
See figure 15 for the -"-H NMR spectrum (4 00 MHz, CDCI3)
of the N-7 6 glycosylation isomer of 6B.
Condensation of Glvcosylation Product (6B)
with Cyclopenta-PAH amino alcohol (7)
The condensation reaction of 6B with 7 to synthesize a
protected N^-deoxyguanosine adduct of a cyclopenta-PAH was
based in part on the procedures of Bartczak et al. (1989),
Hildebrand et al. (1990), and Wright and Dudycz (1984).  The
reaction sequence, shown in figure 8, included the following
steps.
Trans acenaphthene l-amino-2-ol (7)
The enantiomeric l-amino-2-hydroxy cyclopenta-PAH
mixture 7 was previously synthesized by Bartczak and co-
workers according to their published procedures (1989).
N^-ri-ftrans-2-hydroxy-acenaphthenYl)1-0^-p-
nitrophenylethyl-9-(2-deoxy-3.5-di-O-p-toluoyl-fi-D-erYthro-
pentofuranosvl) purine (8)
A mixture of 6B (58 mg, .081 mmol), cyclopenta-PAH
amino alcohol derivative 7 (15 mg, .081 mmol), and
triethylamine (.01 mL, .081 mmol) in 2-methoxyethanol (5 mL,
b-p. 124°C) was refluxed with stirring for 24 h.
The solvent was removed on a rotary evaporator at 90°C
to give a brown syrup which was placed on silica gel
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preparative TLC plates developed with 5% xnethanol-19%
acetone-76% toluene.
Products from ten resolved bands were screened by UV-
visible spectroscopy for the acenaphthene chromophore, and
the presence of N^-modified deoxyguanosine derivatives was
confirmed by FAB mass spectrometry.
The fraction containing compound 8 (Rf=0.70)
chromatographed directly below starting material 6B,
fluoresced light blue under long wave UV, and was isolated
as a light yellow oily residue (3.5 mg, 5%) which showed the
following characteristics:  UV-visible spectrum (methanol)
(see figure 16) - ^max ~  224,280 nm; FAB Mass Spectrxun full
scan (see figure 17(A)) - m/z 821 (MH)"*".  FAB MS/MS (see
figure 17(B)) - m/z 821.1315 (MH)'*'; 803.1281 (MH-H20)'*';
469.1427 (MH-dR+H)"^; 451.6453 (MH-dR-H20+H) ͣ^.
Ammonolysis of Glycosylation Product (6B)
The procedure for the ammonolysis of 6B was based on
procedures of several investigators:  Wright et al. (1987);
Kazimierczuk et al. (1990); Himmelsbach et al. (1984) ;
Trichtinger, Charubala, and Pfleiderer (1983); and Aerschot
et al. (1988).  The methods involved use of either
concentrated aqueous ammonia in methanol or anhydrous
ammonia in methanol with the latter proving more efficient
in removing the 3',5' p-toluoyl groups to yield the desired
compound 9.
UV-vlsible   Spectrum   (methanol)   of  FractionContaining  N^-C 1-(trans-2-hyclroxy-acenaphthenyl))-0^-p-nitrophenylethyl-9-(2-deoxy-3,5-di-0-p-toluoyl-
0-D-erVthro-pentofuranosyl)purine   (8)
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The reaction sequence, shown in figure 8, was repeated
nine times in order to optimize reaction conditions and to
generate sufficient amounts of compound 9 for use in future
condensation reactions.  Reaction conditions for optimal
yield are as follows.
2-Bromo-0^-p-nitrophenylethyl-2^-deoxyinosine (9)
Anhydrous ammonia was bubbled through a stirred, cooled
(0°C) suspension of compound 6B (40 mg) in methanol (20 mL)
until the solution was saturated (approximately 10 min).
The mixture was then stoppered and stirred at room
temperature until the off-white solid dissolved in the
solution (approximately 9 h).  The methanol and ammonia were
then removed on a rotary evaporator under oil pump vacuum at
room temperature.
The clear residual was chromatographed on silica gel
preparative TLC plates eluted with 5% methanol in
chloroform, and the lowest band (Rf=0.27) afforded a
clear/white solid, pure compound 9 (15 mg, 56% yield).
Additional bands resolved by the prep TLC chromatography
gave products identified as NPE-group-deprotected
derivatives of 6B, which will be discussed further in
Chapter IV.
The structural identity and purity of compound 9 were
confirmed by the following characteristics:   Melting Point
86-89'C.  ^H NMR (400 MHz, DMSO-dg) (see figure 18) -
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H5', H5") ; 3.84-3.87 (IH, m,   H4') ; 4.39 (IH, Itl, 0H3') ; 4.81
(2H, t, Jave=6.55 Hz, OCH2CH2) ; 4.92-4.94 (IH, Itl, 0H5') ;
5.35 (IH, m, H3'); 6.33 (IH, pseudo t, Jave=6-65 Hz, HI');
7.63,8.17 (2H each, 2d, J=8.6 Hz each, phenyl Hs); 8.57 (IH,
s, H8).  FAB Mass Spectrum (see figure 19) - m/z 480,482
(MH)"^; 364,3 66 (MH-dR+H) "^; 215,217 (MH-dR+H-NPE group) "^i
Accurate Mass of MH"*" - observed 480.4261, 2.9 ppm
difference from calculated value for CigHiaOeNs  Br^+H.
Condensation of 0^-NPE-Protected 2-Bromo-2'-deoxyinosine (9^with Cyclopenta-PAH amino alcohol (7)
The second condensation reaction involving 2-bromo-2'-
deoxyinosine derivative 9 and the same cyclopenta-PAH
derivative 7 (see figure 8 for synthetic scheme) was carried
out according to the same published procedures as the first.
The reaction steps were as follows.
N^-f1-(trans-2-hydroxy-acenaphthenyl)1-o^-p-
nitrophenylethyl-2'-deoxyquanosine (10)
A mixture of 0^-NPE-protected 2-BrdI 9 (50 mg, .10
mmol), cyclopenta-PAH amino alcohol 7 (35 mg, .19 mmol), and
triethylamine (.014 mL, .10 mmol) in 7 mL methoxyethanol was
refluxed under argon with stirring for 26 h.  The solvent
was removed on a rotary evaporator at 95°C, and the
resulting brown syrup was placed on reversed phase
preparative TLC plates developed with 80% methanol in water.
Products from the ten resolved bands were screened by
UV-visible spectroscopy for the acenaphthene chromophore and
then subjected to FAB mass spectrometry, which failed to
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detect the MH"*" molecular ion (m/z=585) corresponding to
compound 10.  According to UV-visible and mass spectral
behavior, the most promising fraction (band 8, Rf=0.24,
fluoresced light blue under long wave UV) was selected and
purified by HPLC using the following solvent program (%
methanol in water at 2 mL/min):  5 min at 70%; 70 to 100% in
20 min; and 100% for 10 min.  UV-visible and ^H  NMR spectra
were recorded for products from the major peaks that eluted
after 15 min (3.5 mg) (see figures 20 and 21).
UV-visible spectra (methanol) suggested the presence of
the adduct 10 in band 8 ( ^max 280, 224 nm; figure 20), and
in the ^H NMR spectrum (400 MHz, CD3OD), both aromatic and
deoxyribose proton resonances were observed, further
supporting the presence of 10 (figure 21).  However, the
molecular ion could not be confirmed by FAB MS so additional
HPLC was performed on band 8 using the following solvent
program:  5 min at 55%; 55 to 85% in 15 min; and 85 to 100%
in 10 min.  A peak eluting from 28-36 min (2.5 mg of
product) gave suggestive UV-visible and ^H NMR spectra (see
figures 22 and 23), but it was still not possible to confirm
10 by FAB MS.
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CHAPTER IV
RESULTS AND DISCUSSION
Synthesis of 0^-NPE-Protected 2-Bromohvpoxanthine
The synthesis of 0^-NPE-protected 2-bromohypoxanthine
(4) was carried out according to the (somewhat vague) three-
step procedure of Raju, Robins, and Vaghefi (1989), who
claim that 2-bromo-O^-p-nitrophenylethylpurine "can be
prepared on a large scale in 75% overall yield, without
requiring chromatographic purification in any step during
its preparation".  However, in the two separate syntheses
conducted in this study, modifications were required
regarding work-up, and yields were less than published
values.  See figure 7 for the synthetic scheme.
The first step in the sequence, involving tritylation
of 2-bromohypoxanthine (1), proceeded according to the
reference (Raju, Robins, and Vaghefi 1989), but the
resulting sludgy residue containing compound 2 couldn't be
weighed in order to determine the reaction yield (which was
reported as being quantitative).
The second step in the sequence, involving introduction
of the 0^-NPE group to generate compound 3, necessitated
some variations from referenced procedures.  Despite
attempts in two separate syntheses, crystallization of
tritylated 2-bromo-O^-p-nitrophenylethylpurine (3) from 2-
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propanol failed to give pure 3 but rather a precipitate
shown by -"-H NMR analysis (400 MHz, CDCI3) to contain phenyl
impurities (possibly triphenylphosphine oxide side product).
This impure reaction mixture was used in the next step,
involving detritylation with 80% acetic acid, but the
reaction failed to generate compound 4.  Hence, column
chromatography of the reaction mixture was required in order
to obtain pure compound 3 prior to proceeding in the
synthesis.  Best results in separating the N-9 and N-7
isomers of 3 from impurities were obtained by initially
using benzene:chloroform (1:3) as eluant followed by pure
chloroform after appearance of the fraction containing the
N-9 isomer of 3.  The N-7 isomer of 3 eluted later.
The structure and purity of the N-9 and N-7 isomers of
3 were confirmed by their ^H NMR spectra (400 MHz, CDCI3)
(see figure 9), and spectra agreed with all proton signals
reported by Raju, Robins, and Vaghefi (1989) for the N-9
isomer, including two triplets for the methylene protons on
NPE group, two doublets for phenyl protons on NPE group, a
multiplet for the trityl group, and a singlet for H-8 of the
purine.  Integration of the NMR signals verified the proper
number of protons.  ͣ' ͣH NMR signals for the N-9 isomer of 3
were shifted downfield from the corresponding N-7 isomer
signals, as illustrated by the following examples:  for the
N-9 isomer - singlet for H-8, 6 = 7.92 ppiti, and downfield
triplet for CH2, 6 = 4.79 ppm; for the N-7 isomer - singlet
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for H-8, 6 = 7.87 ppm, and corresponding downfield triplet
for CH2 6 = 4.11 ppm.
The yield of compound 3 (combined N-9 and N-7 isomers)
from compound 1 was 28% in the first synthesis and 14% in
the second.  However, in the second synthesis some of the
N-7 isomer of 3 remained on the column and was not included
in the yield calculation.  Since a larger yield of 85% was
reported for this step (Raju, Robins, and Vaghefi 1989),
there is some discrepancy observed in this study, possibly
resulting from the crystallization procedure.
In the third step of the sequence, involving
detritylation of 3 with 80% acetic acid to generate compound
4, a novel work-up technique was successfully employed to
obtain pure 4.  This involved (2 X) trituration of the
reaction product with chloroform to give a precipitate,
determined to be pure 4.  Chloroform was chosen because
compound 3 and side products (trityl alcohol and trityl
acetate) are highly soluble in this solvent while compound 4
shows little or no solubility in it.
The yields of 4 from 3 were 85% and 84% in the separate
syntheses, close to the reported quantitative yield (Raju,
Robins, and Vaghefi 1989).  However, in this study the
overall yields of 4 from 1 were only 24% and 12% in the
separate syntheses in contrast to the published value of
"overall 75% yield" (Raju, Robins, and Vaghefi 1989).
The ͣ' ͣH NMR spectrum (400 MHz, DMSO-dg) of compound 4
(see figure 10) concurred with published data from Raju,
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Robins, and Vaghefi (1989) and showed the following
characteristic signals:  one triplet for methylene protons
on NPE group (other triplet was obscured by a peak from
water), two doublets for phenyl Hs on the NPE group, singlet
for H-8 on purine, and singlet for H-9 on purine (shown at
13.5 ppm on spectra with spanning 0~20 ppm).
Lewis Acid Catalyzed Glycosylation of 0^-NPE-Protected2-Bromohypoxanthine
The glycosylation of 0^-NPE-protected 2-
bromohypoxanthine (4) with the deoxyribose derivative (5A)
(see figure 7 for synthetic scheme) involved use of a
silylating agent, BSA, and the Lewis acid catalyst, TMSOTf.
Methods employed by Raju, Robins, and Vaghefi (1989) and
Wright and Dudycz (1984) were followed for the reaction
procedures and work-up.
Glycosylation products that eluted from prep TLC on
silica gel were (first) a mixture of N-9 a and 6 isomers (Rf
= 0.4) and (later) a mixture of N-7 a and 6 isomers (Rf=0.2)
with the relative amounts of N-9:N-7 equal to approximately
4:1 and 6 anomer/a anomer approximately 45% /55%.  Yield of
the N-9 a and 6 glycosylation mixture was acceptable at 56%.
However, several attempts at separating the anomers by
various combinations of prep TLC plate thicknesses and
eluant mixtures proved unsuccessful.
Raju, Robins, and Vaghefi (1989) reported that their
Lewis acid catalyzed glycosylation reaction between compound
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4 and 1,2,3,5-tetraacetylribose gave 95% yield of the N-9 B
isomer with a ratio of 20:1 for N-9:N-7.
The mechanism of the Sjjl Lewis acid catalyzed
glycosylation reaction between the sugar cation and
nucleophilic purine site (N-7/N-9) is discussed in the
literature by Niedballa and Vorbruggen (1974) and Dempcy and
Skibo (1990).  As shown in figure 24(A), initial silylation
should occur at the N-9 position rather than the N-7
position due to steric effects from the NPE group.
Following removal of the silyl group by the catalyst anion,
ribosylation with the sugar cation (at H-1') would afford
the N-7 isomer as the major kinetic product (see figure
24(A)).  However, under thermodynamic reaction conditions
(long reaction time in a polar solvent) the more stable,
less sterically congested N-9 isomer should be favored.
Niedballa and Vorbruggen (1974) investigated these
"silyl" glycosylation reactions extensively.  They detected
only the S anomer of the glycosylation products in the
presence of a 2a-acyloxy (e.g., -OAcetyl group) sxibstituent
in the sugar moiety.  On the other hand, they found both
anomeric (a and 6) glycosylation products to be formed in
the case of acylated 2'-deoxyribose derivatives.
In fact, Niedballa and Vorbruggen (1974) reacted a
silylated pyrimidine with chlorofuranose (compound 5B in
figure 8) and "in a number of experiments found a nearly
constant ratio of anomers a/fi a> l which apparently could not
be influenced by variation of the reaction conditions".
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KINETIC PRODUCT
m ' ͣ^.
Me—Si—Me
anion" (from catalyst)
OAc
OAc
THERMODYNAMIC
REACnON CONDITIONS
favor less sterically
congested N-9 product
^ I '.H
Beta Attack
f     O      Stable 1,2-o^-acyloxonium
Salt
Fig. 24. Reaction Mechanism of Lewis Acid Catalyzed
Glycosylation. (A), Under Kinetic Conditions-
N-7 Isomer as Major Product (modifed from
Dempcy and Skibo 1991, p. 779); (B), With
2-oc-Acyloxy Sugars - ^ Anomer
As Exclusive Product (modified from Niedballa
and Vorbruggen 1974, p. 3657).
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They further explained the exclusive formation of R
anomers in the case of 2-a-acyloxy sugars as a result of
formation of the rather stable 1,2-a-acyloxonium salt.  This
cyclic sugar cation hinders a attack by the purine
nucleophile during the glycosylation reaction, as shown in
figure 24(B).
Thus, the reaction mechanism proposed in the literature
explains the formation of a anomers in the Lewis acid
catalyzed glycosylation reaction carried out in this study.
However, from Raju and co-workers' report (1989), one would
expect much higher ratios of N-9/N-7 glycosylation isomers
than were observed in this study.  This suggests that the p-
nitrophenylethyl protecting group on 0-6 of the purine may
not be as effective in sterically hindering N-7
glycosylation reaction as Raju, Robins, and Vaghefi (1989)
claim.
In this study, distinction of the N-9 glycosylation
isomers from the N-7 isomers was made by analogy to ^H NMR
data reported for other 2'-deoxynucleoside glycosylation
products, including reports by Wright and Dudycz (1984),
Kazimierczuk et al. (1984), and Kazimierczuk et al. (1990).
In all of these investigations, the N-7 isomer (a or 6
anomer) was differentiated from the N-9 isomer (a or 6
anomer) by key spectral features:  the H-8 signal of the N-7
isomers is shifted downfield from both the phenyl H doublets
and the H-8 signal of the N-9 isomers; and the H-4', H-5',
and H-5" signals of the N-7 isomers overlap, compared to the
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more resolved signals of the N-9 isomers.  In addition, the
a  anomers can be distinguished from the 6 anomers by the
fact that the H-1' signal of the S anomers is a pseudo-
triplet, while the H-1' signal of the a anomers is a broad
"pseudo" doublet. The -^H NMR spectrum of the a and 6
anomeric mixture of N-9 glycosylation product 6A (figure 11)
shows the expected behavior of the NMR signals including:
an upfield shift of singlet for H-8; resolution of multiplet
signals for H-4',H-5', and H-5"; and both a pseudo-triplet
signal for H-1' (6 anomer) and a broad doublet signal for
H-1' (a anomer).
Sodium Salt Glycosylation of 0^-NPE-Prot6cted2-Bromohypoxanthine
Since the products of Lewis acid catalyzed
glycosylation of compound 4 with deoxyribose derivative 5A
could not be separated to give the desired pure N-9 fi
glycosylation product, another glycosylation reaction
mechanism was sought that could ensure separable
glycosylation isomers, preferably with the N-9 B anomer as
the predominant product.  Published reports (Niedballa and
Vorbruggen 1974) and unpublished results in Dr. Gold's lab
indicated that the Lewis acid catalyzed glycosylation of
silylated purine derivatives with chlorofuranose (5B)
produced mixtures of a and B anomers not readily separable.
Thus, in this study it was decided to try the sodium
hydride catalyzed glycosylation of compound 4 with
chlorofuranose 5B (see figure 8 for synthetic scheme).  The
\:'m^^m--^~Vicr--
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"sodium salt glycosylation" method has been reported to
yield only B anomers, with the 9-B isomer as major product
and the 7-B isomer as minor product (Kazimierczuk et al.
1984, 1990).  The reaction mechanism is thought to involve
an 3^2 attack of the anionic purine nitrogen (N-7/N-9) on
the a-anomer of the 1-chloro sugar (5B) (Kazimierczuk et al.
1984, 1990).
In this study both sodium salt glycosylations of 4 with
5B gave N-9 6 and N-7 B isomeric products.  These
glycosylation products were easily separated and purified by
column chromatography on silica gel by utilizing an initial
eluant of 4% acetone in toluene to elute the N-9 B isomer
and later 6% to 10% acetone in toluene to elute the N-7 6
isomer.  No N-7 or N-9 a anomers were detected from the
reaction.
The yields of the desired N-9 B isomer (compound 6B)
were moderate and consistent at 39% and 34% for two separate
reactions.  The relative amounts of N-9 6 isomer/N-7 6
isomer were also consistent at 42% /58% and 44% /56%, but
were in strong contrast to the expected results.
Introduction of the bulky p-nitrophenylethyl group at 0-6 of
the purine was expected to favor formation of N-9 B isomeric
product over N-7 B product, in accord with the report by
Raju, Robins, and Vaghefi (1989) for the Lewis acid
catalyzed glycosylation of compound 4. Other investigators
(Kazimierczuk et al. 1984, 1990) have also reported results
of sodium salt glycosylations of 2,6-disubstituted purines.
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which show the expected predominance of N-9 6 glycosyiation
products over N-7 &  isomeric products as follows (N-9 B/N-7
B):  for 2,6-dibromo - 88% /12% ; for 2,6-bismethylthio -
76% /24% ; and for 2,6-dichloro - 82% /18%.  For 6-
chloropurine the N-9 B/N-7 B ratio was 84% /16%.
Based on results of both the Lewis acid catalyzed and
sodium hydride catalyzed glycosylations in this study, the
0^-NPE protecting group does not seem to be providing
suitable steric hindrance for significantly limiting
glycosyiation at the N-7 position of the purine.  This might
be due, in part, to the fact that the p-nitrophenylethoxy
group could rotate about the C-6 - 0-6 single bond, which
would consequently reduce its steric interference with
attack at N-7.  For the sodium salt glycosylations, the
"large" bromine group on the 2 position of the purine may be
more effective in directing N-7 (vs. N-9) glycosyiation than
the 0^-NPE protecting group is in hindering N-7 reaction.
This suggestion is supported by results of this study, in
which the N-7 isomeric product predominated slightly in the
two sodium salt glycosyiation reactions.
Confirmation of the structure and purity of the N-9 6
glycosyiation isomer (6B) and the N-7 6 isomer was obtained
from their ^H NMR spectra and mass spectrum (for 6B) (see
figures 13, 14, and 15).  As expected, the NMR signal for
H-8 of the N-7 6 glycosyiation product was downfield (5=8.37
ppm) from the H-8 signal of the N-9 B product (6B) (6=8.07
ppm), and the multiplet signal for H-4',5', and 5" of the
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N-7 S isomer strongly overlapped (6=4.64-4.70 ppm) compared
to the corresponding multiplet signal for the N-9 6 isomer
(partially resolved: 6=4.64-4.69 ppm; 4.74-4.77 ppm).
The NMR spectrum of compound 6B (see figure 13) showed
all of the signals expected for the 6 anomer of a protected
2'-deoxynucleoside, including the following:  two singlets
for methyl protons of the p-toluoyl groups; a multiplet for
H-2',2"; two triplets for the methylene protons of the NPE
group; a multiplet for H-4',5',5"; a multiplet for H-3'; a
pseudotriplet for H-1' (characteristic of 6 anomers); six
doublets (12 H total) for phenyl Hs on NPE and p-toluoyl
groups; and an "upfield" singlet for H-8 of the purine.
The FAB mass spectrum of compound 6B (see figure 14)
showed characteristic ions for loss of bromine and loss of
the ribosyl derivative as well as the expected molecular ion
(MH'*' m/z=716,718) .  Also, an accurate mass measurement of
the molecular ion confirmed the elemental composition of
C34H30O8N5'^^Bri.
Condensation of Glycosylation Productwith Cyclopenta-PAH amino alcohol
Since a 2-bromo-2'-deoxyinosine derivative (compound
6B) was successfully synthesized in this study, its
usefulness as a precursor to N^-modified 2'-deoxyguanosine
(a protected DNA adduct of a CP-PAH) could be tested.  Thus,
the coupling of compound 6B with enantiomeric l-amino-2-
hydroxy cyclopenta-PAH (7), was attempted (see figure 8 for
synthetic scheme).
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Trans acenaphthene l-amino-2-ol (7) was available from
earlier work by Bartczak (1989) in which the condensation
with 6-chloropurine-9-B-D-ribofuranose had been accomplished
to generate the diastereomeric N°-adenosine adducts
(Bartczak et al. 1989).  Refluxing ethanol was used as the
solvent for the condensation reaction in that study.  Other
condensation reactions (Hildebrand et al. 1990; Wright and
Dudycz 1984) between 2-bromohypoxanthine and amines employed
refluxing 2-methoxYethanol.
In this study refluxing 2-methoxyethanol (B.Pt.=124°C)
was chosen for initial attempts at the condensation of
compound 6B with 7.  A few drops of triethylamine were added
to neutralize HBr formed during the substitution.  The
reaction was monitored by analytical TLC (silica gel 0.2 mm
layer sheets) until no changes could be observed, during
which time the solution changed in color from light yellow
to green to light brown.  After 24 h, the reaction appeared
complete and was terminated.  Work-up by chromatography on
silica gel prep TLC plates gave ten reaction products
resolved in separate bands.  The products were characterized
by fluorescence (under long wave UV), UV-visible
spectroscopy, and FAB mass spectrometry (in a full scan
mode).
In prior unpublished laboratory results, the UV-visible
spectrum of an acenaphthene-deoxyadenosine (dA) adduct had
been recorded and showed a characteristic shape with ^max
at 223 nm and 275 nm.  From the condensation reaction in
87
this study, product from the prep TLC bands that
chromatographed directly beneath starting material 6B showed
a UV-vis spectrum similar to that of the acenaphthene
chromophore (see figure 16) and also fluoresced light blue
under long wave UV as expected.  FAB mass spectrometry on
this reaction product confirmed the presence of the
protected acenaphthene-deoxyguanosine derivative (8), as
shown by its molecular ion (MH"*" m/z=821) (see figure 17(A)).
As shown in figure 17(B), further support for the adduct was
obtained by FAB MS/MS on this molecular ion which gave
fragments for loss of water (from the acenaphthene alcohol
moiety) and loss of the protected ribosyl derivative from
both the molecular ion and dehydrated fragment.
The band containing compound 8 yielded 3.5 mg of
product giving a yield of -^5% Because the cyclopenta-PAH
derivative (7) was an enantiomeric mixture, coupling with
the D-ribose would be expected to yield diastereomers of 8;
however, they were not resolved by TLC work-up nor were the
spectroscopic techniques applied to characterization of
structure appropriate to demonstrate the mixture.
Although the yield was low (most likely due to the
instability of compound 7) in this initial experiment, the
condensation demonstrates that the 2-BrdI derivative (6B) is
a suitable precursor for generating target N^-deoxyguanosine
adducts.  An attempt was made to improve the yield of the
coupling reaction by removing the bulky p-toluoyl protecting
groups of compound 6B.
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Ammonolysis Reactions on Glycosvlation Product
Two types of ammonolysis reactions for deblocking 3'
and 5' acyl groups of the deoxyribose derivative have been
reported (Trichtinger, Charubala, and Pfleiderer 1983;
Himmelsbach et al. 1984;  Wright et al. 1987; Aerschot et
al. 1988; and Kazimierczuk et al. 1990).  They are use of:
(1) concentrated aqueous ammonia in methanol, and (2)
anhydrous ammonia in methanol.
In this study both ammonolysis procedures were used on
compound 6B in order to generate 0°-NPE-protected 2-bromo-
2'-deoxyinosine (compound 9) (see figure 8 for synthetic
scheme).  After several repetitions with varying conditions
(namely, length of reaction), the methanelie/anhydrous
ammonia method gave desired product 9 in good yields ranging
from 51% - 63%.  Optimal yields were achieved when the
saturated methanolic ammonia solution with 6B was allowed to
stir at room temperature until the white solid starting
material completely dissolved.  Reaction time for 40 mg of
6B was approximately 9 hours.
During all of the ammonolysis reactions conducted in
this study, numerous side-products were observed on prep
TLC, which were identified by -^H NMR spectroscopy or mass
spectrometry.  In two initial anhydrous ammonia/methanol
reactions which were allowed to stir overnight (19-21 h),
five products were obtained to which the following
structures have been assigned:  band 1, p-toluoyl amide;
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band 2, 2-bromo-2'-deoxyadenosine; band 3, p-
nitrophenylethanol; band 3, a 2-bromo-2'-deoxyadenosine
derivative in which the 3' p-toluoyl group remained; and
band 4, the desired compound 9.
As shown in figure 25, the -^H NMR spectrum (4 00 MHz,
DMSO-dg) of the side-product from band 2 matches signals
expected for 2-bromo-2'-deoxyadenosine (see NMR data from
Wright et al. 1987; Kazimierczuk et al. 1990: sharp singlet
at 8.33 ppm for H-8, broad singlet at 7.83 ppm for NH2, a
pseudo-triplet at 6.24 ppm for H-1', and the remaining
signals corresponding to deoxyribose protons).  The NMR
spectrum clearly shows absence of the p-nitrophenylethyl
group for this product by lack of phenyl proton doublets and
methylene proton triplets.  It was not possible to obtain
confirmatory mass spectral evidence; however, during
preparation of this report it was discovered that a
modification in standard technique was required in order to
obtain mass spectra of bromo-9-ribosylpurines.  It is not
possible to repeat spectroscopic analysis on side-products
from the ammonolysis reactions because of insufficient
amounts of remaining products.
Material from band 3 appeared to contain a mixture of
two products - p-nitrophenylethanol and a 2-bromo-2'-
deoxyadenosine derivative with p-toluoyl group intact at the
3' position.  This suggestion is based upon the ͣ' ͣH NMR
spectrum (400 MHz, DMSO-dg) shown in figure 26.
o
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Fig. 25.  ^H NMR Spectrum (AOO MHz, DM50-dg) of Side-Product in Ammonolysis Rxn -
Possibly 2-Bromo-2'-deoxyadenosine.
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Integration of the NMR signals in figure 26 shows that
the phenyl H doublets at 7.50 ppm and 8.14 ppm are in 1:1
ratio with triplets at 2.85 ppm and 3.65 ppm, but are not in
a reasonable ratio with any signals for the deoxynucleoside.
Therefore, this product must result from p-nitrophenyl-
ethanol generated by partial deprotection of O^, and the NMR
signals for this alcohol side-product do match the NMR
spectrum (figure 28) subsequently obtained for pure NPE-
alcohol.
The NMR spectrum in figure 26 also shows signals
expected for a deoxynucleoside without the 0-6 protecting
group but possessing one p-toluoyl group, as evidenced by
two phenyl H doublets at 7.24 ppm and 7.76 ppm, the absence
of the expected triplets in 1:1 integral ratio, and by the
presence of deoxyribose proton signals in the correct
integral ratios.  Since the multiplet signal for H-5',5"
(3.49-3.61 ppm) concurs with that of 2-BrdI (figure 18) and
does not show a downfield shift, the p-toluoyl group is
assigned to the 3' position of the deoxyribose.  With a
singlet resonance at 7.89 ppm consistent with presence of an
amino group, the second product's NMR spectrum is in accord
with a derivative of 2-bromo-2'-deoxyadenosine in which a p-
toluoyl group remains on the 3' position.
A confirmatory mass spectrum of the 2-BrdA derivative
could not be obtained; however, in view of the modified
technique discussed above, this result is inconclusive. The
presence of p-nitrophenylethanol as a side-product was
phenyl H from
p-nitrophenylethanol
Dns from
snylethanolCHj pro^p-nitroph
impurity
H    from
uoyl group
phenyl
OH-5'
J'v.
8 . 7 6 5 4 • J   PPM  ͣ 2
'   Fig.   26.   ͣ'•H  NMR  Spectrum   (400  MHz,   DMSO-dg)   of  Side-Product   in  Ammonolysis  Rxn   -   Possiblya   2-Bromo-2'-deoxyadenosine   Derivative.
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verified by its mass spectrum (EI mode) (see figure 27)
which shows the expected molecular ion (M"^ m/z=167) plus
ions for loss of formaldehyde and loss of water.
In subsequent anhydrous ammonia/methanol reactions
which were terminated upon dissolving of the starting
material (-^ 9 h), at least five products were obtained which
were identified as the following:  band 1, starting material
6B; band 2, 5'-deblocked 6B; band 3, p-nitrophenylethanol
(minor); band 4, 3'-deblocked starting material 6B; and band
5, desired compound 9.  The identity of p-nitrophenylethanol
was established by its mass spectrum (identical to earlier
spectrum) as well as an -"-H NMR spectrum (400 MHz, DMSO-dg)
(see figure 28) that showed signals expected for the phenyl
Hs (two doublets), methylene protons (two triplets), and
hydroxy1 group (broad singlet) in the proper integral
ratios.
In one aqueous ammonia (28 - 30% NH3)/methanol
reaction, side-products including p-toluoyl amide, 2-bromo-
2'-deoxyadenosine, a 2-BrdA derivative in which the 3' p-
toluoyl group remained, and p-nitrophenylethanol were
formed, identified by their -^H NMR spectra and (for NPE-
alcohol and p-toluoyl amide) mass spectra.
Thus, in the ammonolysis reactions carried out in this
study, some displacement of the alkylated 0-6 by ammonia can
be inferred by the presence of p-nitrophenylethanol, 2-
bromo-2'-deoxyadenosine, and the 3'-protected derivative as
side-products.  However, the published reports claim that
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the 0-6 NPE blocking group "is stable against ammonia and
triethylamine in methanol, dioxane, and water but can be
cleaved quantitatively to regenerate the starting materials
by DBN or DBU in aprotic solvents" (Himmelsbach et al.
1984) .
Trichtinger, Charubala, and Pfleiderer (1983) also
report that prolonged treatment of an N^-acylated, 0°-NPE
protected deoxyguanosine with concentrated ammonia in
methanol "cleaves the N^-acyl group without harming the 0
blocking group".  Aerschot et al. (1988) mention that "MeOH
saturated with ammonia hardly caused any deprotection"
regarding removal of the 0-6 NPE group.
The structural identity and purity of compound 9 were
confirmed by ͣ'"H NMR and mass spectra, shown in figures 18
and 19.  The NMR spectrum showed all signals expected for
the 0°-NPE-protected purine base coupled at N-9 to 2'-
deoxyribose in a B anomer configuration.  The FAB mass
spectrum showed the expected molecular ions (MH"^ m/z=480,
482) as well as ions corresponding to loss of deoxyribose
and loss of the NPE group.  Also, an accurate mass
measurement of the molecular ion verified the elemental
composition of CigHisOeNs^^Bri.
Condensation of 0^-NPE-Protected 2-Bromo-2^-
deoxyinosine with Cyclopenta-PAH amino alcohol
Since an 0^-NPE-protected derivative of 2-bromo-2'-
deoxyinosine (9) had been successfully synthesized, it was
coupled with enantiomeric trans acenaphthene l-amino-2-ol
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(7) to generate protected N^-deoxyguanosine adducts of a
cyclopenta-PAH (10) (see figure 8 for synthetic scheme).
With the bulky p-toluoyl groups removed, it was hoped that
yields would be improved relative to condensation with the
fully protected 2-BrdI, and the resulting adduct product
could then be easily transformed into a true deoxyguanosine
adduct by removal of the NPE group with DBU.
Procedures for the second condensation reaction were
similar to the first. 2-methoxyethanol was used as the
solvent for the reflux, but this time argon was passed
through the apparatus during the reaction to help prevent
oxidation of the cyclopenta-PAH. Work-up of the reaction
mixture was carried out on reversed phase prep TLC plates
due to the more polar nature of the products.
Ten bands were resolved on the plates, and all products
were screened for the acenaphthene-deoxyguanosine adduct by
UV-visible spectroscopy and FAB mass spectrometry (in a full
scan mode) . Mass spectra failed to detect the MH"*" molecular
ion (m/z=585) in any band, but revealed an ion at m/z=584 in
one fraction.  This fraction (6.5 mg), which corresponded to
the slow-migrating band 8 on prep TLC plates (Rf=0.24),
fluoresced light blue under long wave tJV and showed a UV-
visible spectrum similar to that of the acenaphthene-dA
adduct.  It was decided to purify this promising fraction by
reversed phase HPLC and then to repeat spectral analysis.
Major peaks eluting at longer retention times were
collected, but the trace showed no clear resolution of the
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expected diastereomers.  In synthesizing N -adenosine
adducts, Bartczak et al. (1989) were able to separate the
diastereomeric adduct mixtures by reversed phase HPLC.
Product (3.5 mg) from the HPLC purification showed a
promising UV-visible spectrum (see figure 20) with a Xxnax ^^
280 nm, similar to the acenaphthene-dA adduct.  -^H NMR
spectroscopy on this product (see figure 21) revealed a set
of signals with integral ratios suggesting a product
containing both a deoxyribose moiety as well as a PAH
moiety.  The spectrum was not definitive, however, due to
impurities, so additional HPLC purification was repeated to
give 2.5 mg of product from the major eluting peaks.  Again,
diastereomers were not resolved.
As shown in figure 22, the latter product's UV-visible
spectrum (methanol) showed a wide absorption peak with ^max
at 280 and 295 nm.  Mass spectrometry on this product again
failed to confirm the molecular ion expected for the
protected N^-modified deoxyguanosine. As mentioned
previously in this report, the technique for obtaining the
mass spectrum was probably in error, and it is not possible
to repeat the analysis due to lack of any remaining adduct
product.  The -"-H NMR spectrum (500 MHz, DMSO-ds) of the
twice-purified adduct was also not definitive because of
interferences.  However, the partial •' ͣH NMR spectrum in
figure 23 shows better resolution of the proton signals in
the aromatic region than was observed earlier.
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Thus, presence of desired compound 10 could not be
confirmed on the basis of the spectra obtained, although
some indication of the protected acenaphthene-deoxyguanosine
adduct product was seen.  If the protected adduct was indeed
generated from this condensation reaction, the yield would
have been approximately 4% (based upon the weight of the
final purified product).  Most likely, the very high
temperatures (>130°C) of the refluxing 2-methoxyethanol
contributed to decomposition of the cyclopenta-PAH starting
material (7), adversely affecting the reaction yields.
CHAPTER V
CONCLUSIONS AND RECOMMENDATIONS
Summary and Conclusions
The objectives of this study were met.  During the
synthetic reactions, important results were obtained, which
provide a basis for continued research as well as
recommendations for improvement in future synthetic
strategies.
As shown in figures 7 and 8, a straightforward
synthetic route, which has not been reported in the
literature, was developed for the synthesis of an 0^-NPE and
p-toluoyl group protected derivative of 2-bromo-2'-
deoxyinosine (6B).  This successful strategy involved sodium
salt glycosylation of 0°-NPE-protected 2-bromohypoxanthine
(4) with chlorofuranose (5B) to give desired pure N-9 6
glycosylation product (6B) in 39% yield.
Although the three-step synthesis of compound 4 was
lengthy and not as straightforward or as efficient as
reported (Raju, Robins, and Vaghefi 1989), it could be
applied with minor modifications to yield pure 4 in adequate
amounts.
An important observation is that the 0-6 p-
nitrophenylethyl group does not appear to direct the
formation of the N-9 6 isomer in the sodium salt
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glycosylation product as was expected on the basis of
literature reports (Raju, Robins, and Vaghefi 1989).  The
protecting group seems to function primarily to facilitate
separation and purification of the isomeric products.
Compound 6B was successfully condensed with trans
acenaphthene l-amino-2-ol (7) to generate the first example
of a protected N -deoxyguanosine adduct of a cyclopenta-PAH
(compound 8) in<v5% yield.
The p-toluoyl groups can be removed by aitimonolysis of
compound 6B to yield O -NPE-protected 2-bromo-2'-
deoxyinosine (9) in 63% yield.  Again, no procedures have
been published for this compound either.
p-Nitrophenylethanol and 2-bromo-2'-deoxyadenosine were
identified ammonolysis reaction side-products by
spectroscopic analysis.  They support the significant
finding that the 0-6 NPE protecting group can be removed
during prolonged reaction, in contradiction to literature
reports (Trichtinger, Charubala, and Pfleiderer 1983;
Himmelsbach et al. 1984; Aerschot et al. 1988).
As a final step, condensation of compound 9 with the
cyclopenta-PAH amino alcohol 7 was carried out, and,
although indicated, formation of the desired adduct
(compound 10) could not be confirmed in the initial
experiment, possibly due to impurities or error in the
spectroscopic technique.  However, the first successful
condensation reaction did prove the usefulness of the
protected 2-bromo-2'-deoxyinosine derivative (6B) as a
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precursor to target N -deoxyguanosme adducts of a
cyclopenta-PAH (with potential application to other
genotoxic chemicals).
In the condensation reactions, the low yields (*/4-5%)
presumably resulted from decomposition of the CP-PAH amino
alcohol (7) due to very high refluxing temperatures.  Even
though the yields were low, even a few milligrams of
synthetic adduct compounds will be sufficient amounts for
future application as chromatographic standards in -^2p_
postlabeling assays.
In order to generate the completely deprotected N^-
deoxyguanosine adduct of a CP-PAH, a final treatment with
DBU to remove the 0-6 NPE group remains to be accomplished.
For use as synthetic standards, N^-modified deoxyguanosine
adducts would, in addition, need to be converted to their
3'-phosphorylated derivatives by procedures that were also
not tested in this study.
Recommendations for Future Research
The synthesis of O -NPE-protected 2-bromohypoxanthine
did not proceed quite as smoothly or successfully as
anticipated based on published reports (Raju, Robins, and
Vaghefi 1989).  Yields were much lower than reported.  Also,
based on results in this study, the function of the 0-6 NPE
group in directing glycosylation to the N-9 6 isomer is
questionable.  During future syntheses, these reaction
procedures should be examined carefully to attempt to
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increase yields to the reported values.  Investigation of an
alternative 0-6 protecting group, such as a benzyl group,
might also be considered and may offer a less time-
consuming, more successful strategy to controlling
regiochemistry of glycosylation.
The effectiveness of the 0-6 NPE blocking group as
claimed in the report by Raju, Robins, and Vaghefi (1989)
could be evaluated by conducting an additional reaction.
Lewis acid catalyzed glycosylation of 2-bromohypoxanthine
with 1,2,3,5-tetraacetylribose should produce only N-9 B and
N-7 B isomeric products.  From this reaction, relative
amounts of N-9:N-7 isomers could then be compared with the
reported ratio of 20:1 for 0^-NPE-protected 2-
bromohypoxanthine in order to determine the magnitude of
difference between the two purine starting materials.
Since the ammonolysis reactions appeared to produce
interesting side-products, further investigation into the
removal of the 0"-NPE protecting group could be undertaken.
Future ammonolysis reactions carried out for over 20 hours
on a greater amount of starting material (compound 6B)
should lead to sufficient amounts of side-products for
satisfactory NMR and mass spectra to confirm identities.
Finally, reaction conditions in future condensation
reactions with amine alcohols should be adjusted to optimize
yields of the desired N^-modified deoxyguanosine adducts.
This could include use of a lower boiling solvent, such as
ethanol, to help prevent decomposition of the cyclopenta-PAH
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amino alcohol, as well as possible alteration of reaction
time.
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